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Abstract 
Toxoplasma gondii (T. gondii) is an obligate intracellular parasite that is widely distributed 
throughout all warm-blooded animals and humans, with a high tropism for the central nervous 
system (CNS). Recent studies correlate chronic T. gondii-infection with behavioral changes in 
rodents; additionally, seropositivity in humans is reported to be associated with behavioral 
and neuropsychiatric diseases. However, little is known about the underlying neurobiological 
mechanisms by which T. gondii might trigger certain neuropsychiatric illnesses.  
In this study we investigated whether the described behavioral changes in a murine model of 
chronic toxoplasmosis are associated with changes in synaptic plasticity and brain neuronal 
circuitry. In mice chronically infected with T. gondii, magnetic resonance imaging (MRI) data 
analysis displayed the presence of heterogeneous lesions scattered throughout all brain areas. 
However, a higher density of lesions was observed within specific regions such as the 
somatosensory cortex (SSC). Further histopathological examination of these brain areas 
indicated the presence of activated resident glia and recruited immune cells accompanied by 
limited alterations of neuronal viability. In vivo diffusion-tensor MRI analysis of neuronal 
fiber density within the infected regions revealed connectivity abnormalities in the SSC. 
Altered fiber density was confirmed by morphological analysis of individual pyramidal and 
granule neurons, showing a reduction in dendritic arborization and spine density within the 
SSC, as well as in the hippocampus. Further evaluation of synaptosome fraction from 
chronically infected mice by proteomic analysis and western blot, revealed significant 
changes in key synaptic proteins, such as PSD95, Synaptophysin, NR1, NR2A and NR2B. 
These persistent impacts of the infection on synaptic efficacy might trigger cognitive and 
neuropsychiatric abnormalities.  
Taken together, these findings indicate that upon latent infection with T. gondii, marked 
neuroanatomical and neurofunctional changes occur in CNS regions that are relevant for 
normal behavior, suggesting a potential explanation for the behavioral alterations, and 
establish a murine model for translational studies of chronic toxoplasmosis.  
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 1 
Introduction 
Toxoplasma gondii (T. gondii) is one of the most studied protozoan parasites world-wide due 
to its importance for human and veterinary medicine. Its versatility to infect a broad range of 
host cells and to successfully evade the host’s immune control makes T. gondii an intriguing 
model to study different aspects of immunology, molecular biology as well as neuro-
immunology. Moreover, its preferential tropism for the nervous system, in line with the recent 
studies correlating chronic toxoplasmosis with behavioral alterations in several host species, 
has turned attention towards potential neurobiological mechanisms by which T. gondii may 
alter brain functions. 
1. Brief description of T. gondii - basic morphology and life cycle 
T. gondii is a heteroxenous (requiring more than one host to complete its life cycle), 
polyxenous (capable of infecting more than one species), and obligate intracellular protozoan. 
It belongs to phylum Apicomplexa, class Conoidasida, order Eucoccidiorida. Like all 
members of Apicomplexa such as Plasmodium spec., Babesia spec. and others, T. gondii is a 
unicellular, spore-forming parasite and able to infect all warm-blooded animals including 
humans (1,2).  
The first identification of the parasite was done in 1908 by Nicolle and Manceaux at the 
Pasteur Institute in Tunis (Tunisia) and in the same period by Splendore in Brazil. The name 
Toxoplasma gondii was proposed by Nicolle and Manceaux based on the morphology of the 
infectious stage (modern Latin. toxo = arc, bow; plasma = shape, form) and the host in which 
it was initially found, the rodent Ctenodactylus gundi (3,4). In the years following its 
discovery, the interest of the scientific community for T. gondii increased, T. gondii-like 
organisms were isolated from several hosts and culminated with the first isolate of viable T. 
gondii from a 3 day old infant presented with encephalomyelitis and retinitis (5–7).  
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The 1990s/2000s were marked by an increased volume of Toxoplasma research and a move 
further from basic parasitology into specialist areas such as immunology, genetics and 
molecular biology. Progressively, detailed reports on infections acquired during adulthood 
have called awareness on the susceptibility to toxoplasmosis of immunocompromised patients 
but also on the association between seropositivity and behavioral, personality and 
neuropsychiatric disorders in immunocompetent individuals (8–14).  
There are three infectious stages of T. gondii: the tachyzoites, the bradyzoites (in tissue cysts) 
and the sporozoites (in oocysts) (15). 
1.1. Tachyzoites 
The term “tachyzoite” (Greek. tachys, fast; zōon, animal) describes the stage that rapidly 
replicates in any cell of the intermediate host and in the intestinal epithelial cells of the 
definitive host. The tachyzoite is approximately 2-6 µm long and 2-4 µm wide, with a pointed 
anterior (apical) end and a rounded posterior end (Figure 1) (15). The apical end is dominated 
by the conoid and the presence of complex organelles such as rhoptries and micronemes. 
Rhoptries are eight to ten club-shaped, unique secretory/excretory organelles found only in 
the Apicomplexa. The secreted proteins called rhopthry proteins (ROPs) have been shown to 
be the key molecules responsible for the virulence of different T. gondii strains (16–18). 
Tachyzoites invade host cells either actively by penetrating the host cell plasmalemma or 
passively by phagocytosis, and form a cytoplasmic vacuole where they start to replicate 
(15,19). Tachyzoites multiply asexually within the host cell by repeated endodyogeny, a 
specialized form of reproduction in which two progeny form within the parent parasite (15). 
The host cell ruptures when it can no longer support the growth of tachyzoites. The newly 
released tachyzoites will infect new host cells, spreading this way the infection. 
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Figure 1. Schematic drawings of a tachyzoite (left) and a bradyzoite (right) of T. gondii (15) 
 
1.2. Bradyzoites 
The term bradyzoite (Greek. brady, slow; zōon, animal) was coined to describe the infectious 
stage in which T. gondii is multiplying slowly within a tissue cyst. The bradyzoite is 
crescentic or oval, each measuring aproximativelly 7 by 1.5 µm in size. Structurally, 
bradyzoites differ only slightly from the tachyzoites. The nucleus is located towards the 
posterior end. The number of rhoptries is lower, as well as their secretory properties, in line 
with the less challenging survival needs of the bradyzoites (Figure 1) (15). Under the pressure 
of the host’s immune response, tachyzoites are transformed into bradyzoites which are 
surrounded by a protective wall and give rise to tissue cyst (Figure 2) (20–22). The newly 
formed wall around the bradyzoites protects them from environmental conditions and the 
host’s immune system allowing the slow multiplication by endodyogeny (15,21,23).  
In the central nervous system (CNS), tissue cysts can be found in any cell type of brain and 
spinal cord parenchyma, are round-shaped and can reach a diameter of 50-70 µm (Figure 2) 
(15). In healthy, immunocompetent hosts, it is presumed that tissue cysts can survive life-long 
inside the host cells or it can be destroyed by the host’s immune system. In 
immunocompromised individuals the cyst can rupture, the bradyzoites transform back into 
tachyzoites and cause recrudescence of infection (2,15,21). 
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Figure 2. T. gondii tissue cyst 
A)  Immunohistological staining of a mouse brain chronically infected, depicting a T. gondii cyst (indicated by 
arrow) located in the cortex. B) Magnified view of the T. gondii cyst from A. Scale bar 100 µm. 
 
1.3. Sporozoites 
Sporozoites develop over the course of several days inside the oocysts that are shed by felids 
into the external environment. Moreover, sporozoites are morphologically similar to 
tachyzoites, 2 µm wide and 6-8 µm long, with a subterminal nucleus (15) and show the same 
infective capacity as tachyzoites being able to actively invade host cells (24,25).   
1.4. Life cycle of T. gondii 
Felids are the definitive host of T. gondii in which asexual reproduction (merogony) and 
sexual reproduction occur in the epithelial cells of the small intestine, leading to the 
production of unsporulated oocysts which are eliminated from the gut together with the feces. 
The maturation of the unsporulated oocysts towards infectious sporulated oocysts takes place 
in the environment, one to five days after being shed (Figure 3) (15,23,26). Infectious oocysts 
can contaminate soil, water or food sources and can remain infective for more than one year 
in unfrozen, moist soil (15,27). Intermediate hosts can be represented by any warm-blooded 
animal; however the first line is usually constituted by small prey like rodents and birds. The 
transmission is mainly horizontal, intermediary hosts become infected after ingestion of food 
or water containing the sporulated oocysts. After ingestion, the wall of the oocysts ruptures 
and the sporozoites invade the host’s intestinal epithelial cells (24,25). Following the invasion 
of the epithelium the sporozoites transform into tachyzoites, which multiply and disseminate 
mostly via immune cells in all organs of the host, with a preferential tropism for the muscles, 
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the eye and the CNS. Once the tachyzoites reached their final destination tissues, under the 
pressure host’s immune system, they go through stage conversion to become bradyzoites and 
give rise to tissue cysts (Figure 3) (21,23,28,29). Humans are considered to be accidental 
dead-end hosts with no significant contribution to the direct life cycle of the parasite. 
Nevertheless, they become readily infected by consuming oocysts contaminated water and 
vegetables or by eating raw/undercooked meat from previously contaminated farm animals 
(Figure 3) (2,28–30).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The complex life cycle of Toxoplasma gondii (29) 
Cats are the definitive hosts in which sexual replication of T. gondii takes place. The fusion of gametes leads to 
the formation of sporozoites containing oocysts that are shed in cat faeces. Sporulated oocysts can contaminate 
food and water, providing a route of infection for intermediate hosts. In the intermediate host acute infection is 
characterized by tachyzoites that disseminate throughout the body. Differentiation to bradyzoites within tissue 
cysts leads to chronic infection. Humans become infected by eating undercooked meat containing tissue cysts or 
by ingesting sporulated oocysts in contaminated water or food. 
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2. Immune response and pathogenesis of Toxoplasma gondii infection 
In immunocompetent individuals the protection against T. gondii infection is mainly 
controlled by complex mechanisms involving an intimate collaboration between innate and 
adaptive cell mediated immunity through the production of inflammatory cytokines and less 
by humoral immunity (29,31,32). In the natural parasitic life cycle, T. gondii infects its 
intermediary hosts by entering the small intestine epithelium following the ingestion of the 
tissue cysts or oocysts.  
2.1. Immunopathogenesis of cerebral toxoplasmosis 
Within the first 3-5 days post infection, in response to parasite recognition and invasion, 
enterocytes produce a set of chemoattractant and activating molecules, but also molecules 
with a direct antiparasitic activity, like nitric oxide (NO) (33–36).  
Up to 7-10 days post infection, a massive infiltration of pro-inflammatory immune cells can 
be observed in the gut (37,38). Several lines of evidence indicate that neutrophils, 
macrophages, dendritic cells (DCs),  CD11c+ and CD11b+ monocytes, and natural killer (NK) 
cells migrate in the intestinal parenchyma, attracted by chemokines and cytokines (38–41).  
Although toxoplasmosis can be associated with multiorgan involvement (liver, heart, lung, 
lymph nodes, eye) the immune privileged brain is the most frequently affected organ. All 
cases of toxoplasmic encephalitis develop as a result of hematogenous spread. Several reports 
indicate that the parasite is able to home in the brain parenchyma as early as 7 days post 
infection, after crossing the blood-brain barrier (BBB) by a Trojan horse mechanism (39,42). 
This is achieved by actively infecting various types of immune cells such as neutrophils, 
monocytes and dendritic cells (39,43,44). Infected leukocytes are able to transport the 
parasites throughout the body as well as to provide protection against host immune defense 
(45,46). In return, the parasite has evolved a way to manipulate host apoptotic pathways, thus 
promoting the survival of both the parasite and the shuttle leukocyte (47,48). To favor 
dissemination to the brain, the parasite-host cell interaction not only allows the survival of 
both cells but may also alter the trafficking of the infected leukocytes as well as the 
expression of specific receptors and/or adhesion molecules to support the diapedesis (49–51).  
A fundamental process in CNS toxoplasmosis is the activation of resident microglia and 
astrocytes in response to the early invasion of the brain extravascular space by tachyzoites 
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along with the infection of astrocytes, microglia and neurons. First signs of glia activation can 
be observed between 7-10 days post infection (52,53). Stimulation of resident glia is 
intimately associated with the recruitment of peripheral T cells and mononuclear cells 
resulting in the development of a T-cell mediated immune response during which  interferon-γ 
(IFN-γ) is the key molecule in the control and elimination of the parasite (54–56).  
T. gondii displays a differential invasive and developmental preference in neural cells in 
relation with the course of infection. Several studies have highlighted the ability of the 
parasite to infect a large number of astrocytes and microglia during the acute stage, in contrast 
with the low number of infected neurons (57–62). However, cysts were found to occur almost 
exclusively in neurons throughout chronic infection (63). 
Early activation of microglia and astrocytes is a mandatory step in the initiation and 
development of immune defense mechanisms necessary for further effective control of the 
parasite multiplication. In vitro and in vivo experiments have shown that following infection 
glia cells can produce a plethora of chemokines and cytokines. For example, astrocytes and 
microglia produce monocyte chemoattractant protein-1 (MCP-1), inducible protein-10 (IP-
10), macrophage inflammatory protein-1 (MIP-1α and MIP-1β) which are involved in 
recruiting peripheral leukocytes to the brain (64). Infection of neurons is also characterized by 
the production of chemokines and cytokines. In vitro experiments using neuron cell cultures 
have demonstrated that cells infected by T. gondii are able to produce interleukin-1 (IL-1), IL-
6, MIP-1α and MIP-1β and thus, contribute to parasite control (65,66).  
As previously mentioned, the recruitment of T cells and peripheral inflammatory leukocytes 
and activation of these cells towards the production of IFN-γ and tumor necrosis factor (TNF) 
is critical for triggering the effective control of the cerebral toxoplasmosis (54–56,67,68). The 
importance of a vigorous adaptive immune response directed against T. gondii during human 
infection is highlighted by the increased susceptibility of patients with primary or acquired 
defects in T cell function (14). Initiation of T cells responses requires that naïve CD4+ or 
CD8+ cells encounter antigen-presenting cells in conjunction with co-stimulatory and 
cytokine signals. During the early stages of infection CD4+ T cells initiate optimal B and 
CD8+ T cell responses, whereas the ability to control the later course of infection is mainly 
attributed to IFN-γ, or expression of CD40L which can activate effector mechanisms in other 
immune cells (69–76). CD8+ T cells are specialized to recognize and destroy infected cells, 
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thus manifesting an essential role in the initiation and regulation of parasite burden during the 
acute stages of infection (69). CD8+ T cells can control the disease through the perforin-
mediated cytolysis of infected cells or by the production of IFN-γ (69,77).  
IFN-γ conveys a signal through a surface IFN-γ receptor to activate signal transducer and 
activator of transcription 1 (STAT1). In response to STAT1 activity effector cells will 
enhance their microbicide and microbiostatic capacities by upregulation of nitric oxide (NO), 
reactive oxygen intermediates (ROIs), immunity-related p47 GTPases (IRGs) and p67 
guanylate-binding proteins (GBPs) which are involved in parasite clearance (29,78–81). IRGs 
constitute a family of hydrolase enzymes which are able to attach to different membranes of 
the intracellular compartments, including the parasite vacuole, and can hydrolyze guanosine 
triphosphate, thus leading to rupture of the vacuole, and subsequent digestion of the parasite 
within the cytosol (78,82–84). Moreover, IFN-γ can induce the expression of certain genes 
implicated in the activation and maturation of several populations of immune cells (80).  
One way for IFN-γ to mediate protective effects to control T. gondii is by inducing increased 
synthesis of nitric oxide (NO) (85,86). NO is produced by numerous cell types implicated in 
the immune response, especially by macrophages (87). Increased NO production is mediated 
by upregulated expression of the inducible NO synthase (iNOS) in response to secretion of 
pro-inflammatory cytokines during infection (85). Although during the early stages of 
infection, NO may limit parasite growth, it is mostly involved in the development of 
pathology (88,89). The specific mechanisms through which NO can interfere with parasite 
survival and replication includes inhibition of the parasite enzymatic activity and direct 
damage of the DNA (90). A second way for IFN-γ to mediate protection against T. gondii 
invasion is by stimulating the synthesis of toxic oxygen radicals by the DCs and macrophages 
(72,91). Involvement of ROIs in their antimicrobial activity was suggested since impairing the 
ability of the cells to generate oxygen intermediates inhibited toxoplasmacidal activity by 
greater than 80% (92).  
Other mechanisms triggered by IFN-γ additionally contributing to the control of the parasite 
replication and burden in the infected hosts are represented by intracellular iron deprivation 
(93) and tryptophan degradation (94). The production, by the infected host cell, of both iron 
and tryptophan is essential for the development of T. gondii, as the parasite is a natural iron 
and tryptophan auxotroph (93,95). 
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TNF is also required for an appropriate immune reaction against T. gondii infection. Several 
studies demonstrated that the blockage of this cytokine results in increased mortality 
approximately 3-4 weeks post infection and higher parasite burden despite having a functional 
IFN-γ response (96–98). TNF synergizes with IFN-γ to promote an anti-parasitic mechanisms 
in macrophages, mediated through the production of reactive oxygen and nitrogen 
intermediates (29,72,73,91,99). Macrophages are professional phagocytes and mediators of 
the host innate response. IFN-γ activated mouse macrophages acquire antimicrobial activity 
that is largely dependent on the production of TNF, reactive oxygen and nitrogen 
intermediates, which consequently leads to parasite damage (29,72,73,91,92,99). Monocytes 
are also required for resistance during toxoplasmosis. Recruited monocytes expressing CCR2, 
after emerging from the bone marrow, home to sites of inflammation in response to CCL2 
enterocytes-produced chemokine. Monocytes exert their role to control the infection directly 
by the secretion of TNF and inducible NO synthase (iNOS) and indirectly by enhancing IFN-
γ production of the CD4+ and CD8+ cells (29,40,41,100).  
In humans, as well as in animal species the outcome of cerebral infection depends on the 
mode of infection, parasite strain, host’s immune system status and host’s genes (101). 
Primary toxoplasmosis with neurological symptoms in immunocompetent individuals is rare, 
and still rare is the presence of neuropathological changes. Microglial nodules containing the 
parasite or encysted forms are occasionally found in the brain of individuals deceased of other 
causes (102).  
In rodents, the development of pathology is not caused by the replication of the parasite but 
rather by the overproduction of IL-12, IFN-γ, TNF and NO leading to a strong Th1 immune 
response (55,101,103). Histopathological features of toxoplasmic encephalitis associated with 
persistent neuroinflammation are widespread astrocytosis and the formation of microglial 
nodules. Moreover, high cellularity, due to peripheral inﬂammatory cells transmigration to the 
brain, the presence of single or paired cysts, parenchymal hemorrhage, edema and areas of 
necrosis can be observed. The inﬂammatory cells are organized in foci, not always 
surrounding the cysts, suggesting the involvement of soluble factors produced by the parasite 
(103–107). 
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3. Toxoplasmosis in Humans 
The world-wide prevalence of T. gondii infection is estimated to 30-70% in human 
populations, although the seroprevalence varies markedly across different geographical 
regions and ethnic groups (1,2,108). Transmission incidence in the human population is 
mostly linked to hygiene and culinary habits, since the contamination may occur via ingestion 
of infectious oocysts from the environment, or tachyzoites and tissue cysts which are 
contained in animal tissues (1,2).  
Toxoplasma infection can be categorized as congenital, acute, or chronic and each may be 
active or asymptomatic.  
3.1. Congenital toxoplasmosis 
Congenital toxoplasmosis implicates materno-fetal transmission via transplacental 
dissemination of the parasite. Early infection of the fetus results in fatal disease comprising 
hydrocephalus, retinal damage and intracranial calcifications. Infection at later stages of 
pregnancy might have long-term effects such as retino-choroiditis and impaired intellectual 
functions (2,109–112).  Several lines of evidence indicated congenital exposure to T. gondii 
as a risk factor for developing schizophrenia spectrum disorders or other psychiatric 
abnormalities in young adults (113–115). 
3.2. Acute toxoplasmosis 
In individuals with intact immune systems, acute infection acquired after birth is usually 
asymptomatic or presents with mild flu-like symptoms. Rare complications associated with 
infection in the normal immune host include pneumonia, myocarditis, encephalopathy, 
pericarditis, polymyositis and ophthalmological lesions (116). Few cases of disorientation, 
anxiety and depression have been noted in patients with acute toxoplasmosis (117).  
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3.3. Chronic toxoplasmosis 
Long-standing infection with T. gondii has generally been considered of little clinical 
consequence, however in the last years this dogma has been questioned by findings which 
raised awareness on the possible roles played by chronic toxoplasmosis in the etiology of 
different mental disorders ranging from behavioral and personality alterations to severe 
psychiatric disorders. 
3.3.1. Cognitive, motor and personality alterations associated with T. gondii infection 
First investigations into the potential effect of T. gondii on human behavior were performed in 
1950s/1960s. Several groups reported a high prevalence of T. gondii infection in patients from 
institutions for mental disorders or in children manifesting changes of personality, slow 
learning capacities and low intelligence quotient (118). Although the authors could not 
confirm that altered mental and cognitive performance is definitely attributed to infection with 
T. gondii, these initial studies opened a venue for further investigations on the potential 
association between cognitive performance and parasitism.  
In 2001, the first report on the potential impact of T. gondii on psychomotor performance was 
published (119). Using a standard computerized test on volunteer blood donors, infected and 
uninfected, the authors conclude that individuals with latent infection exhibited increased 
reaction times, scored more poorly at a standard computerized test and appeared to lose their 
concentration more quickly (119).  
More recently, Beste et al. investigated the possible modulatory role of latent T. gondii 
infection on cognitive functions in elderly individuals (120). Based on a test measuring the 
goal-directed behavior differences between humans with latent toxoplasmosis and uninfected 
controls were detected. When confronted with an auditory deviant stimulus elderly 
individuals with positive immunoglobulin G (IgG) T. gondii serum concentrations revealed 
delaying processes of attentional allocation and disengagement (120).  
Furthermore, the implications of the subtle alterations in psychomotor performance on the 
human behaviour were assessed. Association of T. gondii infection with delayed reaction and 
the impaired ability for long-term concentration may account for the observations from three 
independent groups indicating that individuals chronically infected with T. gondii had a two 
times higher risk of traffic accidents (10,12,121–123).  
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However, a recent study by Stock et al. revealed a paradoxical improvement of cognitive 
control processes in T. gondii infected healthy individuals, arguing therefore for a rather 
positive effect of infection on cognitive capacities than the commonly held view that latent 
infection is detrimental for the host (124,125).  
Also of interest is the hypothesis that chronic toxoplasmosis can alter human personality 
profiles. Throughout various studies, Flegr et al. have administered personality questionnaires 
on several cohorts of university staff and students, military servicemen, blood donors, both 
men and women, and compared individuals with or without antibodies to T. gondii in order to 
identify correlations between chronic infection and personality traits (10,126–128).   
Interestingly, the results revealed prominent gender differences in personality shift. Men were 
more likely to disregard rules, were more expedient, jealous, suspecting, loyal, stoic, low 
novelty seeking and dogmatic. By contrast, infected women were more rules bound, dutiful, 
warm, easy-going and out-going, conforming and moralistic. Both, men and women had 
higher guilt proneness (self-doubting, worried, self-blaming) than the uninfected individuals 
(10,126–128).  
3.3.2. Association of latent T. gondii infection and psychiatric disorders 
Perhaps of greatest interest is the proposal that chronic infection with T. gondii could exert a 
role in the etiology of certain psychiatric disorders in humans.  
The most substantial body of evidence gathered to date relates to the potential association 
between T. gondii and some cases of schizophrenia. Schizophrenia is a chronic, 
neuropsychiatric disorder with a complex etiology and clinical symptomatology, that affects 
approximatively 1% of the adult population (129). Several studies emphasized that 
schizophrenic patients have an increased incidence of T. gondii infection compared with 
control volunteers (114,130–133). The result of two independent meta-analyses of 38 and 42 
studies, carried out in several countries, revealed that T. gondii seroprevalence was 2.7 times 
greater in schizophrenic individuals than in the general population (134,135). Moreover, other 
studies suggested that individuals with increased levels of T. gondii IgG antibodies (indicative 
of chronic infection) are at high risk of developing more severe symptoms of psychoses 
(136,137). Further evidence supporting a possible association between T. gondii and 
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schizophrenia/psychosis is shown by the ability of antipsychotic drugs (i.e haloperidol) to 
inhibit the growth of tachyzoites in vitro (138,139). 
Increased incidence of seropositivity for T. gondii has also been reported in cases of major 
depression, bipolar disorders, obsessive-compulsive disorder (OCD), anxiety and panic 
disorders (140–143). Interestingly, OCD symptoms in individuals infected with T. gondii 
have been reduced by treatment of the infection alone (144). Depression is associated with 
self-directed violence and suicide. It is estimated that more than half of the individuals 
suffering from depression had a suicide attempt, making suicide the 10th leading cause of 
death worldwide (145,146). Several studies have identified a positive correlation between T. 
gondii infection and suicidal behavior. The first reports of a relationship between T. gondii 
infection and suicidal behavior were published in 2009 by Arling et al. and in 2010 by 
Yagmur et al., which confirmed the association between T. gondii IgG, but not IgM 
antibodies (indicative of acute infection), and suicide attempts (146,147).  
In addition to the links of T. gondii to schizophrenia, mood disorders and OCD, chronic 
infection with T. gondii has been suggested to be associated with Alzheimer’s (148) and 
Parkinson’s disease (149,150), autism spectrum disorders (151), Tourette’s syndrome (152), 
epilepsy (153) and headaches (154,155).  
Importantly, all reports mentioned above demonstrate that only a certain percent of the 
patients suffering from a neuropsychiatric disease have a chronic infection with T. gondii and 
not all immunocompetent individuals infected with T. gondii are at risk of presenting 
neurologic involvement. Therefore, no direct causal relation between the infection and 
psychiatric disorders could be established. Different theories discuss the genetic 
susceptibility, route of infection (tissue or oocytes), number of ingested parasites, and/or 
timing of infection (congenital, childhood or adulthood) as important factors in the 
development of neurological manifestations (13,125).  
Overall, these studies suggest that T. gondii infection in humans may result in deviating 
behaviour and could have substantial health implications.  
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4. Toxoplasma gondii infection and animal behavior 
Infection with T. gondii is highly prevalent in the rodent population, up to 35% of wild rats 
show serological evidence of exposure to the parasite (156). A number of studies have 
demonstrated that long-standing infection is associated with significant alteration in rodent 
behaviour. In 1980, Hutchinson et al. reported that infection with T. gondii in mice is 
associated with an increased amount of general movement but decreased rearing and digging 
(157). Similar results have been observed in wild or laboratory rats chronically infected with 
T. gondii (158–160). In addition to increased locomotor activity, infected rats display reduced 
neophobic behavior compared to uninfected ones (158). The definitive hosts of T. gondii, cats, 
are major predators of mice and rats. They show little interest in stationary objects, but are 
easily attracted to movement (161,162). It is presumed that increased exploratory activity and 
mobility of infected rodents will lead to increased predation thus, allowing the parasite to 
complete its life cycle.  
Interestingly, new data indicate a more complex ability of T. gondii to manipulate the 
behavior of rodents in relation to predator-prey interactions. The infection not only reduced 
the instinctive aversion of rodents to cat odor, but instead attracted them (160,163–165). 
Furthermore, this behavioral adaptation might not be an epiphenomenon as it seems to be 
highly specific towards cat odour and not due to destruction of the olfactory regions of the 
brain or to altered anxiety-like behavior, learned fear and nonaverse learning (166,167). 
Another recent study, which used an identical murine model of toxoplasmosis as implemented 
in our study, reported motor coordination and sensory deficits but normal cognition in 
infected mice which was associated with widespread parasite cysts and no specific tropism to 
a certain brain region (168). Contrary to previous findings, experiments conducted by 
Gatkowska et al. described reduced exploratory activity in T. gondii infected mice, however 
these behavioral changes were mainly pronounced in the acute stage (169).  
In conclusion, all studies conducted in different experimental models indicate that certain 
behavioral changes occur upon acute and chronic T. gondii infection. However, the 
underlying neurobiological mechanisms by which T. gondii alters brain functions remain 
largely unclear.  
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5. Hypotheses for specific behavior changes in intermediate hosts 
Research performed in the last years, mainly with animal models, has provided several 
hypotheses which may explain the behavioral and neuropsychiatric deficits. These rationales 
are mostly centered on the ability of the parasite to interfere with the survival and activity of 
the neurons it infects.  
5.1. Cyst location in the CNS 
The location of the cysts has been suggested to play an important role in the behavioral 
changes of the host.  In rodents, parasite cysts were found to persist in many areas of the CNS, 
such as the olfactory bulbs, forebrain, cortex, striatum, amygdala, cerebellum and spinal cord 
(104,164,166,170–172). One report indicated a higher density of cysts in the amygdala of 
infected mice, proposing a possible explanation for the instinctual fear loss towards feline 
odor (166). Amygdala is a brain structure, which is part of the limbic system and involved in 
fear, memory and reward modulation (173,174). However, up to date most of the studies 
argue against the tropism of the cysts towards a specific brain region and question the 
effective manipulation of the host behaviour without a well targeted tropism of the parasite 
(172,175). 
In humans, less information is available on the presence and location of cysts in individuals 
chronically infected with T. gondii. These studies mainly focused on immunocompromised 
hosts that suffered from reactivated toxoplasmosis (176–178). Conejero-Goldberg et al. have 
investigated the presence of T. gondii in the frontal cortex of postmortem specimens from 14 
individuals with schizophrenia, 11 with other psychiatric diagnoses and 26 normal 
individuals. All specimens, from all individuals, were negative (179). The limited number of 
information could be due to the complications of accessing postmortem material as well as the 
effect of the methods used to process postmortem brain samples, which may destroy the T. 
gondii cysts. 
5.2. T. gondii modulates dopamine production  
One of the most appealing hypotheses to explain neuromodulatory effects of T. gondii 
infection is based on the capacity of the parasite cysts to disturb dopamine metabolism. In 
2009, Gaskell et al. found two genes in the genome of T. gondii, which encode tyrosine 
hydroxylase, the rate-limiting molecule for dopamine synthesis (180). Interestingly, in 2011 
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Prandovszky et al. reported, using in vitro as well as in vivo approaches, that parasite cysts 
harbored inside neurons express tyrosine hydroxylase as well as dopamine (181). Moreover, 
there was a threefold increase in the amount of dopamine released in infected cells,  compared 
to uninfected ones (181). These results lead to the hypothesis that excess of dopamine 
produced by the parasite could interfere with crucial brain functions (i.e. locomotion, 
cognition, memory, mood, learning, reward) directly influencing the behaviour of the 
intermediary host (182). In humans, dopamine and dopamine signaling pathway 
dysregulations have been associated with several neurodegenerative and psychiatric disorders 
like schizophrenia and Parkinson’s disease (183–186). However, the information provided by 
the limited number of animal studies on this topic, are not conclusive and even contradictory 
(187,188).  
5.3. T. gondii can functionally “silence” neurons 
Recently, Haroon et al. reported that T. gondii tachyzoites directly modulate neuronal 
function by active manipulation of  Ca2+ signaling upon glutamate stimulation, thus, leading 
to either  hyper- or hypo-responsive neurons (164). Moreover, activity-dependent uptake of 
the potassium analogue thallium was decreased in neurons containing the cysts, implying an 
inhibited function of the neurons. All major structures of the neurons contained parasite 
antigens, thus the enlargement of the neurons itself may further contribute to the impaired 
neuronal activity. Importantly, both bradyzoites and tachyzoites functionally silenced infected 
neurons, which may contribute to the host’s behavior changes (164). 
5.4. Proteins injected by T. gondii can manipulate host cell 
Two different studies described the capacity of T. gondii to inject ROPs into the cell it invades 
in order to intersect different host cell transcription factors and thus, impairing the capacity of 
the host to produce defensive molecules (189,190). Recently, another study presented 
evidence that T. gondii can actually inject ROPs in a large number of host cells without 
effectively invading the respective cells (191). Koshy et al. found that ROPs can manipulate 
the uninfected cells in a similar manner to infected cells. However, it is not clear if these 
proteins remain active for long term within the injected neurons. Although the study reveals a 
net effect of the injected effector proteins on host cell transcription factors (i.e STAT6) 
involved in immune response, no evidence of other functional and/or morphological 
dysregulations are provided. Nevertheless, these studies open a new direction for research 
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suggesting that cyst persistence in different brain regions is not mandatory to interfere with 
host behavior.  
5.5. Persistent behavioral changes after parasite clearance 
More recently, Ingram et al. (165) in a quest for unraveling the underlying mechanisms of the 
pathogen-mediated behavioral changes have explored the contribution of the three major 
clonal lineages of T. gondii to the loss of innate aversion of cat urine. Interestingly, they have 
used an attenuated Type I strain and provided evidence of sustained loss of aversion at times 
post infection when neither parasite nor ongoing brain inflammation were detectable (165). 
This suggests that the behavioral change could be due to a specific, hard-wired alteration in 
brain structure, which is generated early during infection and is independent of parasite 
presence. This finding casts doubt on hypotheses discussed above that cysts or dopamine can 
cause the behavioral changes associated with T. gondii infections.  
 
It is worthy to highlight that behavioral alterations, in rodents as well as  in humans, were also 
detected upon other parasitic infections, such as Heligmosomoides polygyrus, Toxocara canis 
or Eimeria vermiformis (192–195). Importantly, these parasites do not directly infect the 
CNS, suggesting an even more complex peripheral or apparently global, indirect, 
neuromodulatory effect rather than direct alterations of neuronal function. 
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6.  Neuroplasticity and neuroinflammation 
Expression of behavior or mental illness is directly regulated by biological functions of the 
brain. Physiologically, the function of the brain is to exert centralized control over the other 
organs of the body and to adaptively integrate the body to the broad environmental conditions.   
6.1. Overview on neuronal anatomy and plasticity 
Neurons represent the morphological and functional units of the brain. The brain contains 
between one billion and one trillion neurons, depending on the species. The functional 
property that makes neurons unique is their ability to send high-speed electrical signals to 
specific target cells over long distances (196). The neuron consists of a cell body containing 
the nucleus, cytoplasm, and an electrically excitable output fiber, the axon, which projects to 
variable distances to other neurons (i.e. from a cortical pyramidal neuron to adjacent cortical 
neurons, or to spinal cord motoneurons) (Figure 4, left panel) (196). Many axons are covered 
with a layered insulating myelin sheath, made of specialized glia cells, which speeds the 
transmission of electrical signals along the axon. Most of the space in the brain is occupied by 
axons, which are bundled together in what are called nerve fiber tracts. All nerve fiber tracts 
create a complex map of neural connections or the brain wiring diagram (196).  
Additionally, neurons have a number of other, generally shorter projections like the branches 
of a tree, called dendrites. Their function is associated with the reception of signals from other 
neurons. The interneuronal communication takes place at the level of dendritic spines, which 
are membranous protrusions from the neuronal surface located mostly on dendrites. The spine 
is a structure specialized for synaptic transmission (Figure 4, middle panel) (196,197). 
Synapses (Greek. synaptein, to clasp together) are key functional contact points where one 
neuron communicates with another. Synapses can be of two types: chemical or electrical. In a 
chemical synapse, the electrical signal of the presynaptic neuron is converted into the release 
chemicals called neurotransmitter (such us glutamate, γ-aminobutyric acid (GABA), 
dopamine, serotonin), which further bind to receptors located on the postsynaptic neuron (like 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) or N-methyl-D-aspartate 
(NMDA) receptor). In turn, this triggers an electrical response or a second messenger pathway 
that may inhibit or activate the postsynaptic cell. In an electric synapse, the presynaptic and 
postsynaptic cell membranes are connected by special channels called gap junctions that are 
capable of passing electric current (196). As mentioned, a synapse has a pre- and a post-
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synaptic compartment. The presynaptic site contains complex molecular machinery dedicated 
to neurotransmitter transport, packing into vesicles, release and re-uptake. The postsynaptic 
element is represented by the postsynaptic density (PSD), a membrane associated disc of 
electron dense material consisting of receptors, channels and signaling systems (Figure 4, 
right panel) (196,197).   
Any alterations in the synaptic compartments trigger changes of the strength or efficacy of 
synaptic transmission at preexisting synapses, a concept termed synaptic plasticity (198). This 
is a dynamic and continuous process, which takes place in response to experiences (like 
learning, thinking, emotions) or environment. Long-term, persistent experiences or bodily 
injury can have an impact not only at the cellular level, but can lead to large-scale 
neuroplasticity changes, involved in brain remapping of neural connections (199,200).  
The study of structural connectivity and neuroplasticity originates from the fact that function 
and structure of the brain are intricately linked (196,197). Investigation of the brain structural 
changes to better understand the functional output can be achieved at different levels of scale. 
At the macroscopical level the only methodology providing a global in vivo noninvasive 
window into the brain is Magnetic Resonance Imaging (MRI), and especially diffusion tensor 
(DT)-MRI and consecutive fiber tractography (201–205). Mapping of the neuroplasticity on a 
neuron-by-neuron level, currently, cannot be accomplished with noninvasive imaging 
techniques, requiring post-mortem microscopic analysis of limited portions of brain tissue 
(206,207).  
6.2. The impact of neuroinflammation on neuroconnectivity 
Inflammation is a response of the immune system that aims to protect and defend living 
tissues. Triggers can be represented by aseptic (i.e. traumatic injury) or septic (such as 
bacterial, viral or parasite pathogens) insults. The attribute of inflammation is the mobilization 
and interaction of several cell types and molecules, resulting in a response that is both local 
and systemic (208,209). Classically, the CNS has been considered to be immune-privileged, 
because, within its boundaries, there is an absence of the typical immune response as seen in 
the periphery (210). However, recent evidence indicates a complex neuroimmune crosstalk 
which is essential for brain homeostasis (211,212). Several hypotheses have proposed that 
CNS injury is associated with abnormal expression of immune mediators, thus 
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neuroinflammation, which might result in synaptic impairment and in subsequent 
destabilization of neuronal networks (213,214).  
 
Figure 4. Schematic description of a neuron and a synapse 
Illustration of a neuron showing the major structural components (left panel), a detailed view of a dendrite and 
dendritic spines (middle panel) and the diagram of a synapse (right panel). When electrical signals reach the end 
of the axon, they trigger the release of neurotransmitters that are stored in vesicles. Neurotransmitters bind to 
receptor molecules that are present on the dendrites of adjacent neurons. These receptors act as on and off 
switches for the next cell. Abbreviation: PSD, postsynaptic density. 
 
6.2.1. Central neuroinflammation 
In addition to the local, relatively limited functional effects of T. gondii cysts on neurons, as 
discussed above, the hallmark of chronic infection is the permanent activation of resident glia 
cells throughout the whole CNS and the recruitment of peripheral immune cells (53,74,215). 
This prolonged neuroinflammation is able to directly influence a large number of neurons 
located in various neuroanatomical areas (213,216,217). Data obtained from studies using 
animal models indicate that, once the CNS is invaded by T. gondii, resident cells as well as 
recruited immune cells induce a chronic neuroinflammatory millieu characterized by the 
predominance of Th1-type (IFN-γ, IL-12, IL-1, IL-6, TNF) immune responses (55,101,103). 
In the last years, research focused on the impact of the broad range of immune responses of 
the CNS on human behavior and neuropsychiatric morbi has received increasing attention 
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(209,214,218). These studies have revealed that patients diagnosed with major depression, 
obsessive-compulsive disorders, and schizophrenia show increased biomarkers of 
inflammation such as IFN-γ, IL-12, IL-1, IL-6 and TNF (218–221).  
Chronic neuroinflammation following acquired infection with T. gondii in immunocompetent 
intermediate hosts can potentially elicit behavioral alterations and neurological disorders by 
triggering subtle alterations in the morphology and functionality of neurons. A considerable 
body of evidence indicates that neuropsychiatric disorders, such as schizophrenia, might not 
be the result of focal brain abnormalities but rather the consequence of pathological 
interactions between several brain regions leading to abnormal integration of brain functions 
(222–225). Deficits in interregional functional coupling can arise from impairments of 
neuroconnectivity due to changes in morphology/distribution of dendritic spines, alterations 
of the synaptic plasticity (i.e. composition of some receptors and their subunits) or white 
matter structural abnormalities (222,226–229).  
Interestingly, in a recent study, Horacek et al. have assessed by voxel-based morphometry 
MRI the changes in the volume of the brain cortex of schizophrenic individuals, with or 
without IgG against T. gondii (230). They report that schizophrenic patients chronically 
infected with T. gondii had significant reductions in grey matter volume of several cortical 
regions as compared with the noninfected patients (230). The anatomic substrate of the grey 
matter volume reduction indicated impairments of neuropil and structural connectivity; 
however, the precise nature of the impairments was not investigated, representing a 
significant omission. 
6.2.2. Neuroinflammation via peripheral mediators 
Immune signals from the systemic millieu are able to initiate neuroinflammatory processes, 
which in turn can cause or accelerate dysfunctions in synaptic plasticity, neurotransmitters 
and their receptors, and neuronal circuitry (Figure 5) (214,231,232). The importance of 
peripheral immune mediators in the pathophysiology of brain disorders has been documented 
for schizophrenia, major depression, Alzheimer’s disease, Huntington’s disease, stroke and 
traumatic brain injury (214,232,233). Similarly to the case of other pathogens known to alter 
host’s behavior (192,193,195), it is likely that neuroinflammation can be induced not only 
following the invasion of the neural parenchyma by the parasite but also by peripheral 
immune stimuli. Before reaching the CNS, within the first 3-5 days post infection, T. gondii 
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triggers systemic inflammation, in response to parasite recognition and invasion, which is 
initiated in the intestine. Thus, the systemic inflammatory millieu also can lead to local or 
global disruptions of neuronal physiology and neuroconnectivity (29,35,234–236). 
 
 
 
Figure 5. Schematic illustration of the brain-periphery crosstalk pathway in the regulation of 
neuroplasticity (232) 
One essential pathway is the neural route, which is achieved through the vagal or adrenergic innervation of 
distant organs. Another important pathway is via the blood, where circulating immune signals (e.g., cytokines, 
chemokines and immune cells) and bioenergetic signals (e.g., endogenous metabolites, microbial products and 
hormones) cross the BBB and exert a systemic impact on the brain microenvironment. These intricate links play 
a profound role in the regulation of neurogenesis and synaptic plasticity. Abbreviations: BBB, blood–brain 
barrier; 5-HT, serotonin; SCFA, short chain fatty acid; GLP-1, glucogan-like peptide 1. 
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Aims 
Studies carried out in recent years emphasized a possible association between chronic 
infection with T. gondii and certain psychiatric disorders and behavioral perturbations 
(10,125,133,146,166). However, little is known about the underlying neurobiological 
mechanisms by which T. gondii might trigger certain neuropsychiatric illnesses.  
Evidence is accumulating for neuro-immune mediated interactions that could contribute to 
psychiatric disorders (218,237). Furthermore, recent data indicates that psychiatric disorders 
might be the consequence of abnormal integration of brain functions (222–225). Deficits in 
functional coupling can arise from impairments of neuroplasticity due to changes in 
morphology/distribution of dendritic spines, alterations of the synaptic plasticity or white 
matter abnormalities (222,226–229).  
The hallmark of persistent T. gondii infection is permanent resident glia cell activation in the 
CNS and production of a plethora of chemokines and cytokines (55,56). Neuroinflammation 
can distinctively influence neuronal morphology and functions (216–218,238). Therefore, it is 
tempting to speculate that T. gondii infection could trigger such impairments of 
neuroplasticity. 
The aim of this thesis was to address the hypothesis that latent T. gondii infection leads to 
defective neuroplasticity in a murine model of toxoplasmosis. The detailed objectives were: 
1) To study the impact of chronic infection with T. gondii on murine brain connectivity 
blueprints. To this end, we first investigated the distribution of T. gondii-induced lesions by 
MRI. In vivo imaging analysis, using diffusion-tensor MRI and a fiber-tracking methodology, 
corroborated with histopathological investigations, allowed us to investigate neuronal fiber 
density and fiber connectivity alterations. 
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2) To examine the effect of chronic infection with T. gondii on the structure of 
individual, noninfected neurons. Therefore, by using DiOlistic labeling on fixed acute brain 
slices, we performed detailed analysis of the dendritic morphology of mature pyramidal 
neurons. Additionally, we investigated if dendritic spine density and morphology in 
noninfected neurons were impacted by infection.  
3) To investigate the role of chronic infection with T. gondii on the integrity and 
functionality of synapses. Dendritic spines abnormalities predict changes in the information 
trafficking between neurons. To reveal the biology associated with synaptic plasticity, we 
explored the synaptoproteome by mass spectrometry analysis. Additionally, we measured, by 
western blot, the expression level of several proteins that regulate key synaptic functions. 
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Materials and Methods 
1. Animals and T. gondii infection 
All animal experiments were approved, according to German and European legislation by the 
Landesverwaltungsamt Halle (Sachsen-Anhalt, Germany, approval number IMMB/G/01-
1089/11). Experiments were conducted with adult C57BL/6 female mice (8 weeks old, 
purchased from Janvier). Mice were housed in standard lighting conditions (12:12 h light-dark 
cycle) and temperature (21-23°C), 4 to 5 animals per cage, with food and water ad libitum. 
T. gondii cysts of the ME49 type II strain were used for this study. Parasites were harvested 
from mice of NMRI strain, infected with T. gondii cysts 4 to 5 months earlier. Brains were 
isolated from infected mice and dispersed in 1 mL sterile phosphate buffered saline (PBS) by 
mechanically disrupting the tissue followed by several passages through needles with 
regressing diameter.  
Cysts were counted using a light microscope in 10 µl of the brain suspension and the total 
number of cysts per brain was calculated. Three cysts were administered intra peritoneal (i.p.) 
into mice in a total volume of 200 µL/mouse. Control (noninfected) mice were mock infected 
with sterile PBS. 
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2. In vivo Magnetic Resonance Imaging 
This work was done in collaboration with Dr. Laura Adela Harsan and Dr. Dominik von 
Elverfeldt from Department of Radiology, Medical Physics, Animal Molecular Imaging 
Research Center, University Medical Center, Freiburg, Germany (201,203,239). 
Mouse brain MR Imaging was performed on seven infected mice (week 8 p.i.) and nine 
control mice using a 9.4 T (Tesla) small bore animal scanner, equipped with a BGA12S 
gradient system capable of 675mT/m (Biospec 94/20, Bruker, Germany). A transmit/receive 
1H mouse quadrature birdcage resonator (35 mm inner diameter) and the ParaVision 5 
software interface were also used for the acquisition of the MR signal. All imaging procedures 
were carried-out under isoflurane (3% for induction and ~1.5% for maintenance) mixed with 
oxygen (1l/min) anesthesia and using respiratory gating.  
2.1. Data acquisition 
Prior any brain imaging, the magnetic field homogeneity was optimized by performing a 
localized shimming procedure on a volume of interest (4.8 x 5.3 x 9 mm³), selected inside the 
mouse brain on the localizer images. This step of the MRI protocol was designed to correct 
the distortions and signal intensity dropout caused by local susceptibility differences between 
adjacent structures (particularly observed in border regions). For this optimization, we used 
the press waterline spectroscopy protocol as well as FastMap procedures provided with the 
Bruker ParaVision 5 system. 
Morphological T2*- and T2-weighted imaging 
A FLASH 2D sequence was used for T2*-weighted imaging of the whole mouse brain in 31 
contiguous axial slices, acquired with a 78 x 78 x 500 µm³ imaging resolution (TR/TE = 
920/12 ms, flip angle = 60°, 2 signal averages). Acquisition time: 7m52s. RARE T2-weighted 
imaging was performed with the same slice geometry and resolution as described for T2*- 
imaging, using the following parameters: TR/TE = 3675/20 ms, RARE factor = 4 and 4 signal 
averages, acquisition time: 15m40s. 
Diffusion Tensor-MRI (DT-MRI) 
Diffusion MRI data was acquired in 31 axial 500-µm slices, with the same orientation as for 
the previous T2*- and T2-weighted scans, using  a 4-shot DT-EPI sequence [repetition time, 
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7750 ms; echo time, 20 ms; time (∆) between the application of diffusion gradient pulses, 14 
diffusion-sensitizing gradients applied along 45 isotropic directions of three-dimensional 
space, with a b factor of 1000 s/mm2. Six averages were acquired to increase the signal to 
noise ratio (SNR). The in-plane image resolution was 156 x 156 µm at a field of view (FOV) 
of 20 x 20 mm and an acquisition matrix of 128 x 92. Partial Fourier with an acceleration 
factor of 1.35 and 31 over scan lines were used. Off resonance artifacts were eliminated by 
using a fat suppression module (1.9 ms Gaussian pulse, 1400 Hz bandwidth, 2 ms spoiler). 
The resulting total imaging time for the T2*-weighted, T2-weighted and DT-MRI was 
~2h20m for each animal (~24 min for T2*- and T2-weighted images, ~ 115 min for DT-MRI 
acquisition – with respiratory gating) slightly varying depending on the respiratory rhythm of 
each animal.  
2.2. Data post-processing 
DT-MRI data post-processing including tensor calculation, generation of parametric maps 
(fractional anisotropy - FA, mean diffusivity <D>, radial - D┴ and axial - D║ diffusivities) 
and fiber tracking was performed using a FiberTool package developed in-house. 
(http://www.uniklinik-freiburg.de/mr/live/arbeitsgruppen/diffusion/fibertools_en.html).  
A global fiber tracking approach was employed to define the large scale mouse brain 
connectivity networks (201). The global tracking algorithm reconstructed all fiber bundles 
simultaneously, for the whole brain, without the requirement of defining seed or target regions 
(203). The results were used for generating mouse brain fiber density maps (FD) as well as 
highly resolved spatial histograms of diffusion orientations – here named high resolution fiber 
maps (hrFM).  hrFM were tailored to increase eight times the native imaging resolution of the 
diffusion data, reaching a spatial resolution of 19.5 x 19.5 x 62.5 µm³. We used a 
reconstruction approach previously described by Harsan et al. (201) and another group (240). 
Quantitative comparison of T. gondii vs. control group 
Spatial normalization of the mouse brain parametric maps generated from the diffusion data 
(including FA and FD maps) and the morphological T2*- and T2-weighted images was 
performed using Matlab-script that registered the brain maps from all investigated animals on 
a previously created mouse brain template. Group (toxoplasma vs. control group) averaged 
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maps of FA, FD, <D>, D┴ and D║ were created and used for quantitative group comparison. 
White matter (WM), gray matter (GM) and cerebro-spinal fluid (CSF) masks were generated 
using the T2-weighted images and used as regions of interest. An additional region of interest, 
the somatosensory cortex (SSC) was included in the quantification and was manually selected 
based on mouse brain atlas guidelines (241). 
 
3. Histopathological analysis 
Mice were initially anesthetized by intra peritoneal injection of Ketamine-Xylazine (100 
mg/kg ketamine, 5 mg/kg xylazine) and then perfused transcardially with ice cold 4% 
paraformaldehyde (PFA). For histopathological investigation control and T. gondii infected 
brains were immediately removed from the skull and placed in 4% PFA at 4°C. Brain samples 
were then dehydrated in xylol, embedded in paraffin and sectioned coronally at 5 µm with a 
Leica microtome. To evaluate the lesions observed by T2*-weighted MRI sequence, a 
classical examination was performed with hematoxylin and eosin (H&E).  
Moreover, immunohistochemical analysis was performed using primary antibodies against 
ionized calcium binding adaptor molecule 1 (Iba1, 1: 250 Dako, Denmark) to label microglia, 
CD3 (1:150, Dako, Denmark) to label infiltrating T lymphocytes, CD11b (1: 200, Abcam, 
UK) to label infiltrating monocyte derived macrophages, glial-fibrillary acidic protein (GFAP, 
1: 200, Abcam, UK) to label astrocytes, Cleaved Caspase-3 (Asp175, 1:200, Cell Signaling, 
USA) to label apoptotic cells and anti-Toxo (1:200, Dianova, Germany) to label T. gondii 
cysts.  
A Zeiss (Carl Zeiss, Germany) microscope equipped with an AxioCam HRc 3 digital camera 
and AxioVision 4 Software were used to obtain images. A minimum of 6 region-matched 
coronal slices were analysed for each brain. In the anatomical brain regions where the parasite 
was found the following pathological processes were analysed: necrosis, hemorrhage, edema, 
astrogliosis, cellular death and inflammation.  
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4. Immunofluorescence 
For immunofluorescence and Fluoro-Jade B, control and T. gondii infected brains were 
immediately removed from the skull and placed in 4% PFA at 4°C for several days. Each 
brain was sectioned coronally (18µm) using a Leica cryostat (C 3050, Wetzlar, Germany). 
Free floating tissue sections were stored in cryoprotection medium (30% glycerol and 30% 
ethylene glycol) at -20°C until required. The immunofluorescence procedure followed similar 
steps for all tested markers. Coronal sections were routinely prepared and rinsed in 0.1 M 
PBS, pH 7.4.  
Brain slices were first treated with 0.25% Triton X-100 in PBS for 30 minutes at room 
temperature (RT), followed by incubation in 10% normal goat serum (100µl/mL, Vector 
Laboratories, USA) and 0.25% Triton X-100 in PBS for 30 minutes. Immunolabeling with a 
mouse anti-pan-neuronal neurofilament (1:800, clone SMI311, Millipore, Calbiochem, USA) 
and rabbit anti-microtubule associated protein (1:50, MAP2, Cell Signaling, USA) antibodies 
was performed overnight at 4°C, to detect alterations in dendritic and axonal structure. 
Tissue sections were incubated with appropriate (anti-rabbit/anti-mouse) AlexaFluor 488/594 
secondary antibody (1:200, Invitrogen, Germany), for 1.5 hours at RT and protected from 
light. Sections were rinsed in PBS (two times for 20 minutes), and mounted on 1% gelatin 
coated glass slides with ProLong Gold antifade medium with DAPI (Invitrogen, Germany). A 
Zeiss (Carl Zeiss, Germany) microscope equipped with an AxioCam HRc 3 digital camera 
and AxioVision 4 Software were used to obtain images. A minimum of 6 region-matched 
coronal slices were analysed for each brain. Brain areas were assigned according to a mouse 
stereotaxic atlas (241).  
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5. Fluoro-JadeB staining  
To specifically assess neurodegeneration induced by chronic T. gondii infection, Fluoro-Jade 
B (Millipore, Chemicon, USA) staining was performed according to the manufacturer’s 
indications with slight modifications. Sections were immersed in 100% ethanol for 5 minutes 
followed by 70% ethanol (2 minutes) and distilled water (2 minutes). The rehydration step 
was followed by incubation in 0.06% potassium permanganate (15 minutes), then rinsed in 
dH2O (1 minute) and transferred for 30 minutes in 0.0004% FluoroJade B solution in the 
dark. Finally, the sections were rinsed three times in distilled water for 1 minute per change, 
air dried, cleared by immersion in Roti-Histol (Roth, Germany), (2 minutes) before 
coverslipping with DPX (Fluka, Milwaukee WI). On average 4 region-matched coronal 
sections were analysed for each brain. 
 
6. Electron microscopy  
This work was done in collaboration with Prof. Dr. Christian Mawrin from the Institute of 
Neuropathology, Otto-von-Guericke University, Magdeburg, Germany (242,243). 
Coronal brain slides (150-200 µm), corresponding to midd third of the cerebrum, including 
SSC, were cut immediately after perfusion and fixed in phosphate-buffered glutaraldehyde 
(3%), followed by embedding in epon. Prior to trimming, toluidine-blue stained sections (500 
nm thickness) were evaluated for the optimum area for electron microscopic examination. 
Ultrathin section (50 nm) were cut using a Leica Ultracut device, mounted on copper grids 
and stained with lead citrate solution for contrast enhancement. Sections were evaluated on a 
Zeiss-EM 900 electron microscope.  
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7. DiOlistics and morphological analysis 
This work was done in collaboration with Prof. Dr. Martin Korte, Dr. Marta Zagrebelsky and 
Marianna Weller from Zoological Institute, Division of Cellular Neurobiology, University of 
Braunschweig, Germany (206,207).  
Hippocampal neurons from C57Bl/6 control and T. gondii infected mice were labeled, 8 
weeks post-infection, using DiOlistic on fixed acute slices (206,207). Briefly, the mice were 
anesthetized and perfused transcardially with 30 ml of 4% paraformaldehyde and 4% sucrose 
in 0.1 M PBS. The brains were immediately dissected and postfixed in the same solution for 
30 minutes at 4°C. Further, the brains were embedded into 2% agar in phosphate buffered 
saline, cut in 400 µm thick coronal sections with a vibratome (Leica VT 1000 S).  
Tungsten particles (50 mg; 1.7 µm in diameter; Bio-Rad) were mixed with 100 µl of dye 
solution (3 mg DiI, Invitrogen in 100 µl of methylene-chloride, Sigma-Aldrich), dried and 
suspended in 3 ml distilled water. The dye solution was sonicated, diluted 1:80 and used to 
coat the inside of a TEZFEL tubing (Bio-Rad). Dye-coated particles were delivered to the 
acute slices using a hand-held gene gun (Bio-Rad; Helios Gene Gun System) with a pressure 
of 120 psi. A membrane filter (3 µm; Millipore) was inserted between the gene gun and the 
slice to prevent clusters of particles from landing on the tissue. After shooting, the slices were 
kept in PBS for 6 hours at room temperature (RT) to allow dye diffusion. The slices were 
stained with DAPI (4',6-diamidino-2-phenylindole, AppliChem), washed, and mounted using 
an antifading water-based mounting medium (Biomeda).  
The neurons were imaged with an Axioplan 2 imaging microscope (Zeiss) equipped with an 
ApoTome module (Zeiss). Each neuron was first imaged with a 20x objective (0.8 N.A., 
Zeiss) with a z-sectioning of 1 µm. Morphological reconstruction of the neurons and their 
process was achieved with the Neurolucida software (MicroBrightField). Dendritic 
complexity and length of the dendrites were analysed with the Neuroexplorer software 
(MicroBrightField). The cells were analysed up to a distance of 160 µm for DG, 200 µm for 
apical CA1 apical and Cortex Layer II/III and 150 µm for basal CA1 and Cortex Layer II/III, 
to ensure that only completely labeled dendrites were included in the analysis. Moreover, 
spine density, length and spine head width were measured separately for apical and basal 
dendrites. For that, the images of dendrite stretches, from the apical and basal compartments, 
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were acquired using a Leica SP2 confocal microscope with a 63× objective. The number of 
spines was normalized per micrometer of dendritic length.  
The data obtained were compared between the two different experimental conditions using a 
two-tailed Student t test. Asterisks indicate the significance levels as follows: *p <0.05; **p 
<0.01. 
 
8.  Synaptic junction preparation 
Highly puriﬁed synaptic junction proteins fractions were prepared according to a previously 
published protocol by Smalla et al. (244). Brieﬂy, 8 weeks post-infection, animals were 
sacrificed by transcardially perfusion with ice cold PBS. For each individual mouse both, left 
and right, hippocampi together with somatosensory cortices were dissected on ice and stored 
at -80°C until further used.  
For subcellular fractionation, samples were homogenized in buffer A (10 mL/g tissue) 
containing 5 mM HEPES buffer pH 7.4 in a 0.32 M sucrose solution and protease inhibitor 
cocktail (Complete Mini, Roche, Germany). All centrifugation steps were performed at 4°C. 
Homogenates were centrifuged two times at 1000 g for 10 min. Supernatants were collected 
and subjected to another two additional centrifugation steps at 12000 g for 20 min to obtain 
the P2’ pellet (crude membrane fraction). The P2’ pellet was homogenized in  buffer B (1.5 
mL/g tissue; containing 0.32 M sucrose, 5 mM Tris pH 8.1, supplemented with protease 
inhibitors), loaded on a 0.85 M/1.0 M/1.2 M sucrose step gradient and centrifuged at 85000 g 
for 2 hours. Synaptosomes fraction was collected at the 1.0 M/1.2 M sucrose interphase, 
subjected to hypo-osmotic shock by adding 5 volumes of 1 mM Tris/HCl pH 8.1 for 30 
minutes and then spun down at 32000 g for another 30 minutes. After centrifugation, 
solubilized P3 pellets (synaptosomal membranes) were applied to a discontinuous sucrose 
gradient (1.0M/1.2 M) and subjected to ultracentrifugation at 85000 g for 2 h.  
The synaptic junctions were collected at the interphase between 1.0 and 1.2 M sucrose and 
stored at -80°C until further used for western blot experiments. Protein content was 
determined using the Bicinchoninic Acid protein assay kit (Pierce, Rockford) (according to 
manufacturer’s indications). Briefly, samples were mixed with the BCA working reagents and 
incubated for 30 min at 37°C. Absorbance was measured at 562 nm, for each sample the 
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protein concentration was determined by comparison with a bovine serum albumin standard 
curve. 
 
9. Western Blot analysis 
Except the subcellular fractionation to obtain the synaptic junction proteins the rest of the 
western blot analysis was performed with whole brain homogenates. The protein extraction 
procedure is described further. 
For each individual brain, the hippocampus and the ipsilateral cortex from control and T. 
gondii infected mice were dissected as previously described (245,246) and stored at -80°C 
until further required. Prior to use, samples were mechanically homogenized at 4°C in 
TBS/TX buffer (150mM NaCl, 1% Triton X, 50mM Tris, pH 8.0) containing a protease 
inhibitor (Complete Mini, Roche, Germany) and a phosphatase inhibitor cocktail (PhosSTOP, 
Roche, Germany). The homogenates were subsequently centrifuged (18000 rpm, 15 min, 
4°C) and the supernatant was removed and stored at -80°C until further use. Protein content 
was determined using the Bicinchoninic Acid protein assay kit (Pierce, Rockford) (according 
to manufacturer’s indications).  
Samples containing equal amounts of total protein (10.0 μg), were separated on 10% SDS-
polyacrylamide gels and transferred to polyvinylidene fluoride membranes using a semi-dry 
blotting system (detail). The membranes were soaked in TBS-T solution (0.1% Tween-20, 
0.8% NaCl, 20mM Tris, pH 7.5) containing 5% nonfat dry milk or 5% bovine serum albumin, 
for 1 h at RT, followed by incubation with appropriate primary antibodies. The detailed list of 
primary antibodies used for immunobloting is presented in Table 1.  
After incubation with the primary antibodies, membranes were washed with TBS-T and 
incubated with horseradish peroxidase (HRP)-conjugated swine anti-rabbit secondary 
antibody (1:1700; Dako, Denmark). Blots were developed using a Pierce ECL 2 kit (Thermo 
Scientific, USA). For semiquantitative studies the chemiluminescence signals were captured 
using a ChemoCam Imager (Intas, Germany) and converted into a digital format. The 
immunostained band densities were normalized with respect to the loading control (GAPDH) 
and analysed using LabImage software (Kapelan Bio-Imaging, Germany).  
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All data were analyzed with GraphPad Prism 6 and are shown as mean ± SEM. Statistical 
significance was determined using the unpaired two-tailed Student t test. p values of ≤0.05 
were considered significant.  
 
Antibody 
(clone) 
Mol. Wt 
(kDa) 
Antigen Type Reference Conc (%) 
Akt (pan) 
(C67E7) 
60 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#4691 
1:1000 
pAkt (Thr308) 
(D25E6) 
60 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#13038 
1:1000 
pAkt (Ser473) 
(D9E) 
60 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#4060 
1:1000 
GAPDH (14C10) 37 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#2118 
1:10000 
AMPA1 (D4N9V) 100 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#13185 
1:1000 
AMPA2 (E1L8U) 100 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#13607 
1:1000 
GSK3β (27C10) 46 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#9315 
1 :1000 
pGSK3β (Ser9) 
(D85E12) 
46 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#5558 
1 :1000 
MAP2 (D5G1) 280 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#8707 
1:1000 
NMDAR1 
(D65B7) 
120 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#5704 
1 :1000 
NMDAR2A 180 Human peptide Polyclonal 
(rabbit) 
Cell Signaling 
#4205 
1 :800 
NMDAR2B 
(D15B3) 
190 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#4212 
1 :1000 
PSD-95 (D27E11) 95 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#3450 
1:1000 
Synaptophysin 
(D35E4) 
38 Human peptide Monoclonal 
(rabbit) 
Cell Signaling 
#5461 
1:5000 
 
Table 1. Summary of primary antibodies used for western blot experiments 
Primary antibodies were diluted in TBS-T solution (0.1% Tween-20, 0.8% NaCl, 20mM Tris, pH 7.5) containing 
5% nonfat dry milk or 5% bovine serum albumin, and incubated overnight at 4°C, following manufacturer’s 
indications.  
 
Materials and Methods 
 
35 
10. RT-PCR analysis 
After removal, tissue samples from brains were immediately transferred to RNA later 
(QIAgen, Hilden, Germany). They were kept at 4°C for at least 24 h and then stored at -20°C 
until RNA isolation. For RNA isolation, the tissue was removed from RNA later and 
homogenized with 1mL of TriFast (peqGOLD, Erlangen, Germany) in BashingBeads tubes 
(Zymo Research, Freiburg, Germany). PeqGOLD HP Total RNA Kit was used for 
purification and manufacturer’s instructions were followed. On-membrane DNase I digestion 
(peqGOLD, Erlangen, Germany) was performed and RNA purity and concentration was 
determined by absorbance at 230, 260 and 280 nm in a NanoDrop (Fisher Scientific, 
Germany). 
For qPCR, TaqMan® RNA-to-Ct 1-Step Kit (Life Technologies, Darmstadt, Germany) was 
used with 300ng total RNA in a reaction volume of 10µL. Triplicate reactions were developed 
in a LightCycler® 480 Instrument II (Roche, Grenzach-Wyhlen, Germany). Reverse 
transcription was performed for 15 min at 48°C followed by 10 min at 95°C. Subsequently, 
45 amplification cycles were run, comprising of denaturation at 95°C for 15 sec and 
annealing/elongation at 60°C for 1 min. TaqMan® Gene Expression Assays (Life 
Technologies, Darmstadt, Germany) were used for amplification of Hprt (Mm01545399_m1) 
and Gsk3b (Mm00444911_m1). Hprt expression was chosen as reference for normalization 
and target/reference rations were calculated with the LightCycler® 480 Software release 1.5.0 
(Roche, Grenzach-Wyhlen, Germany).  
Resulting data were further normalized on values of control groups and statistically analyzed 
with GraphPad Prism version 6 (GraphPad Software, Inc., San Diego, CA, USA). All data are 
shown as mean ± SEM. p values of ≤0.05 were considered statistically significant. 
Materials and Methods 
 
36 
11. Proteomic analysis  
This work was done in collaboration with Prof. Dr. Lothar Jänsch and Dr. Marco van Ham 
from Cellular Proteome Research Group, Helmholtz Centre for Infection Research, 
Braunschweig, Germany (247,248). 
11.1. Protein digest 
Cortical and hippocampal synaptosomes were pulled toghether and digested, with trypsin,  in 
50 mM triethylammonium bicarbonate (TEAB) containing 10 % acetonitrile (ACN) and 
phosphatase inhibitors. A protein/protease ratio of no more than 50:1 was applied and 
digestion was performed at 37°C overnight. Peptides were vacuum dried, resolved in 0.2 % 
trifluoroacetic acid (TFA) in water, desalted on self-packed Lichroprep RP18 (10 µl, Merck), 
eluted in 0.2 % TFA in 60 % ACN and dried again.  
11.2. iTRAQ labelling and SCX chromatography 
Isobaric tags for relative and absolute quantitation (iTRAQ) labelling was performed 
according to the manufacturer´s protocol (Applied Biosystems). Briefly, 150 µg dried 
peptides was redissolved in iTRAQ dissolution buffer at a ratio of no more than 50 µg 
peptide/20 µl buffer and incubated with three vials of label for 2 h followed by vacuum 
drying. A small aliquot was used to confirm the minimum percentage of peptide labelling 
using a 30 min RP18 gradient and the OrbitrapVelos mass spectrometer. Labeled fractions 
were combined and employed for Strong Cation Exchange (SCX) chromatography to reduce 
the complexity. The following iTRAQ reporter combinations were used: Toxoplasma-infected 
mice 114; noninfected mice 116. 
The complex peptide mixtures were than subfractionated according to Reinl et al. (249). In 
short, up to 100 µg peptide were separated on a Mono S PC 1.6/5 column (GE Healthcare) via 
an Ettan micro-LC system (GE Healthcare) using a 30 min gradient from 0 to 35 % SCX 
buffer B (0.065 % formic acid, 25 % ACN supplemented with 0.5 M KCl) at a flow rate of 
150 µl/min. Up to twenty 150 µl fractions were collected, desalted and used for LC-MS/MS. 
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11.3. LC-MS/MS and data analyses 
LC-MS/MS analyses were performed on a DionexUltiMate 3000 n-RSLC system connected 
to an Orbitrap Fusion mass spectrometer (Thermo Scientific). Peptides were loaded onto a 
C18 pre-column (3 µm, Acclaim, 75 μm x 20 mm, Dionex), washed for 3 min at a flow rate of 
6 μl/min. Subsequently, peptides were separated on a C18 analytical column (2 μm, Acclaim 
PepMap RSLC, 75 μm x 25 cm, Dionex) at 350 μl/min via a linear 120-min gradient with 
UPLC buffer A (0.1 % FA in water) and 25% UPLC buffer B (0.1 % formic acid in ACN), 
followed by a 60 min Gradient from 25 to 50 % of buffer B. The LC system was operated 
with Chromeleon Software (version 6.8, Dionex) embedded in Xcalibur software (version 2.1, 
Thermo Scientific). The effluent from the column was electro-sprayed (Pico Tip Emitter 
Needles, New Objectives) into the mass spectrometer.  
The mass spectrometer was controlled by Xcalibur software and operated in the data-
dependent mode allowing the automatic selection of a maximum of 10 doubly and triply 
charged peptides and their subsequent fragmentation. A dynamic exclusion allowed up to 3 
repeats.  Peptide fragmentation was carried out using High Collision Dissociation settings 
optimized for iTRAQ-labeled peptides.  
MS/MS raw data files were processed via Proteome Discoverer 1.3.0.339 mediated searches 
against UniProtKB/Swiss-Prot protein database (release 2013_01, with 538,849 entries; 
taxonomy Mus musculus with 16589 entries on a Mascot server (V. 2.4, Matrix Science). The 
following search parameters were used: enzyme, trypsin; maximum missed cleavages, 1; 
fixed modifications, iTRAQ 4-plex (K), iTRAQ (N terminus), Methylthio (C), oxidation (M); 
peptide tolerance, 5 ppm; MS/MS tolerance, 0.2 Da.  
The knowledge-based Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood City, 
CA) was employed to identify networks, canonical pathways, molecular and cellular 
functions, and behavioral and neurological dysfunctions using proteins from iTRAQ data set.
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Results 
1. Experimental design 
All the experiments were performed 8 weeks after infection. This time point was chosen 
because active parasite levels in critical peripheral organs are absent by this time and the 
parasite load in the brain is stable in chronically infected mice (168). 
Initially, mouse brain T2- and T2*-weighted images were acquired at different time points. 
The development and the localization of T. gondii-induced brain lesions were monitored 
starting one week prior to infection, to chronic stages [week 8 post infection (p.i.)] and 
validated by histopathological examination.  
Additionally, at the chronic stage (week 8 p.i.), in vivo mouse brain DT-MRI analyses were 
performed in T. gondii infected and control (noninfected) mice.  
To reveal different aspects of T. gondii-CNS interactions, we also performed:  
 immunofluorescent and electron microscopy experiments 
 investigation of neuronal dendritic and spine morphology 
 synaptosome/synaptic junction preparation and proteomic analysis 
 western blotting (WB) and real time polymerase chain reaction (RT-PCR) experiments 
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2. Distribution of T. gondii induced lesions: MRI vs. histopathological 
investigations 
To determine the pattern of brain microstructural alterations induced by chronic T. gondii 
infection in a murine model, in vivo non-invasive MRI was performed at high magnetic field 
(9.4 T). T2*-weighted imaging was used to identify and anatomically localize the preferential 
lesion sites of parasite induced brain pathology. Multiple foci of hypointensity were 
visualized with T2*-based contrast in various cortical and subcortical brain areas (Figure 6A). 
A pattern of high density of hypointense lesions was evident in the somatosensory (SSC) and 
motor cortices, hippocampus and striatal brain structures of all the infected mice. 
Interestingly, in T2-weighted imaging such regions appeared generally unaffected, 
demonstrating the superiority of T2*-weighted imaging for assessing the T. gondii induced 
brain pathology. To further define the composition of microstructural alterations leading to 
the changed T2*-contrast in the infected mice, brains of mice used for MRI studies were 
analyzed ex vivo using various neuropathological markers (Figure 6B). Scattered 
inflammatory infiltrates were detected throughout the whole brain, as well as only minor 
meningeal alterations and edemas (hematoxylin-eosin staining). We focused our analysis on 
the somatosensory cortex (regions between bregma + 0.14 mm and bregma –1.82 mm), where 
we observed a high density of hypointense lesions on T2* - weighted images of the infected 
mice. The number of T. gondii cysts was randomly distributed with no preference to a specific 
brain area. In each slide, 6 to 10 parasite cysts were detected within the cortex, 1 to 2 cysts 
within the hippocampus and 4 to 6 cysts in the other remaining brain areas. The cyst wall 
around the bradyzoites remained intact and extracellular parasites were not present, indicating 
latent rather than active T. gondii infection (Figure 6B). Interestingly, clusters of activated 
immune cells were not exclusively surrounding the cysts. Activated resident microglia cells 
were distributed ubiquitously in the whole brain with preference for the developing cortical 
inflammatory nodules (Iba1-positive). Activated astrocytes manifested evenly throughout the 
brain parenchyma (GFAP-positive). Moreover, perivascular cuffs were constituted mainly by 
recruited mononuclear cells with few neutrophil granulocytes (CD11b-positive) and 
lymphocytes (CD3-positive) (Figure 6B). Cell apoptosis (indicated by caspase-3 (Casp-3) 
staining) was observed demonstrating cell death as a consequence of chronic T. gondii 
infection. To clarify whether neurons were affected we employed a specific staining (Fluoro-
Jade B) which only detects degenerating neurons. Fluoro-Jade B-labeled cells were observed 
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only sporadically in the inflammatory foci within the cortex and hippocampus, indicating that 
the majority of neurons in those regions did not die (Figure 6B).  
 
Figure 6. Pathological changes identified by MRI and histopathological examination of the murine brain 
chronically infected with T. gondii 
(A) Representative T2*-weighted MR images, acquired before infection (baseline) and at 8 weeks post infection 
(chronic), depicting T. gondii induced brain microlesions throughout four coronal brain slices. Note the changes 
in the lateral and third ventricle size (asterisks) and the localization of the lesions (arrows) within the cortex but 
also in the striatum and along the white matter fiber tracks (ssc, somatosensory cortex; cg, cingulum; CPu, 
caudate putamen, Bg, bregma).  
(B) In the cortical regions where hypointense T2*-weighted lesions were observed, H&E and anti-T. gondii 
staining revealed a higher density of cells, parenchymal micro-hemorrhage, and the presence of intact T. gondii 
cysts. Closer examination using anti-Iba-1 and anti-GFAP antibodies indicated diffuse activation of microglia 
and astrocytes. This was followed by recruitment of CD11b positive cells, indicating microglia cells as well as 
brain recruited macrophages. Numerous recruited T cells were detected by anti-CD3 antibody. Apoptotic cells, 
highlighted by an anti-Caspase-3 staining, were scattered throughout cortical areas. Fluoro-Jade B staining 
revealed a low number of degenerating neurons limited to the inflammatory foci (T. gondii infected mice n= 7; 
four to six coronal slides per mouse were analyzed). Scale bars in B: 100µm, 20µm in insets. 
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3. Chronic T. gondii infection alters the brain connectivity microstructure: 
in vivo qualitative and quantitative DT-MRI 
To investigate the impact of T. gondii infection on the mouse brain neuronal wiring we 
performed a detailed qualitative and quantitative analysis of brain microstructural connections 
using in vivo DT-MRI and high resolution fiber mapping (hrFM). We adopted a novel fiber 
tracking and mapping methodology (201), which provided fine-grained maps of the living 
mouse brain structural connectivity (Figure 7A, B, hrFM). At first, we focused our 
investigation on the SSC showing the highest density of hypointense lesions on T2*-weighted 
images of the infected mice (Figure 7).  
High resolution fiber maps revealed an altered connectivity pattern with a loss in fiber 
coherence and density at the lesion sites (Figure 7B, arrows). Using a special reconstruction 
algorithm (203,240) the resolution of the final fiber maps was increased by eight times (final 
resolution of 19.2 x 19.2 x 62 µm3) vs. the scale of the original DT-MRI data. This allows a 
close comparison with the cortical pattern of axonal cytoskeletal proteins evaluated ex vivo 
with immunofluorescence.  
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Figure 7. In vivo appraisal, by DT-MRI, of cortical injuries induced upon chronic T. gondii infection 
Comparative visualization of T2*-weighted images (a, c) and high resolution fiber maps (hrFM) (b, d) of control 
(A) and T. gondii infected (B) mouse brains. Magnified views show the localization of T. gondii induced injuries 
(arrows) in the somatosensory cortex. Note the changed cortical connectivity pattern (vs. control) and the loss of 
fiber density in infected cortical areas. Brain connectivity maps were generated using a global optimization fiber 
tracking algorithm on data acquired at 9.4 Tesla. Control mice n=9, infected mice n=7. 
 
The impaired cortical connectivity blueprints depicted in vivo in T. gondii infected brains  
(Figure 7B, hrFM) were paralleled by the observation of an abnormal expression pattern of 
the axonal and dendritic cytoskeleton markers Pan-Neuronal Neurofilament (clone SMI311) 
(Figure 8E, F, G) and Microtubule Associated Protein-2 (MAP2) (Figure 8H) in the same 
cortical areas. Clear reductions of the SMI311 and MAP2 immunofluorescence signals were 
detected, unraveling structural abnormalities along the cortical dendritic arbor of infected 
mice (Figure 8). Further analysis by western blot revealed a significant reduction in MAP2 
content in the cortical extracts of T. gondii infected mice (Figure 8I) (relative intensities 
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normalized to GAPDH: control animals, 0.74±0.12; T. gondii infected mice, 0.32±0.08; 
p=0.02; unpaired Student’s t test). Such modifications might not only involve the local 
cortical connectivity, but could influence the overall brain fiber microstructure and wiring.  
 
Figure 8. Structural abnormalities in axons and dendrites were observed within the cortex of T. gondii 
infected mice 
Immunofluorescence stainings with the neuronal cytoskeleton marker, anti-Pan-Neuronal Neurofilament 
(SMI311) revealed structural abnormalities in the axons and dendritic trees within the SSC of T. gondii infected 
(E-F) vs. control mice (A-B). Detailed examination of the cortical layers (dashed squares) demonstrated 
defective morphology of noninfected pyramidal neurons of chronically infected mice (G, arrows) as indicated by 
reduced expression of SMI311 in contrast to normal expression in control animals (C, arrows).  
Parallel immunofluorescence stainings against Microtubule Associated Protein-2(MAP2) confirmed the 
structural alterations of the dendrites within the SSC of T. gondii infected mice (H, arrows) vs. control mice (D, 
arrows). Five to six coronal slides per mouse were analyzed, n=3-4 mice per group. (Scale bars, 1 mm in A and 
E, 200 µm in B and F, 50 µm in C and G, and 100 µm in D and H).  
(I) Western blot analysis of MAP2 content in cortical extracts from control and infected mice, alongside GAPDH 
loading controls. Graph indicates densitometric analysis of blots, expressed as mean±SEM. Analysis was 
performed in three independent experiments. The circles show individual values, from one representative 
experiment. *p<0.05 
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To obtain quantitative insights about the whole brain structural modifications upon T. gondii 
infection, we performed group statistical analysis (control vs. T. gondii infected animals) 
using the brain parametric maps derived after the calculation of the diffusion tensor as well as 
the fiber density (FD) maps generated with our global fiber tracking approach.  
After spatial normalization to a mouse brain template, the brain parametric maps of fractional 
anisotropy (FA), mean diffusivity (<D>), radial (D┴) and axial (D║) diffusivities and FD 
from each individual were group averaged and used for quantitative group comparison. 
Several studies have demonstrated the usefulness of FA, <D>, D┴ and D║to describe 
directional diffusivity of water molecules within the brain, along and across axonal tracts, 
providing meaningful biological information related to axonal and myelin pathology 
(239,250,251).  
Figure 9 illustrates the overall impact of chronic infection with T. gondii on the FD and FA 
values. A general pattern of fiber loss could be noted in the infected group upon comparative 
inspection of group averaged FD maps (Figure 9A). Using a brain mask approach we 
separately assessed the FD modifications in areas of white matter (WM) and grey matter 
(GM) (Figure 9C) that were previously segmented from spatially normalized and averaged 
T2-weighted images. An additional region of interest was manually selected, covering the 
SSC.  
Statistically significant decreases of the FD values were quantified on the WM area (17.8% 
reduction: see Figure 9B; control 0.74±0.07, infected 0.61±0.08; normalized values ranging 
from 0 to 1) as well as on the SSC (23% reduction: see Figure 9B; control 0.39±0.03, infected 
0.30±0.055; normalized values ranging from 0 to 1). Despite the general tendency of a 
decrease in FD values over the whole GM brain area, the difference did not reach the level of 
statistical significance, mostly because of a high variability across the T. gondii infected 
mouse population. 
Moreover, a comparable pattern of pathologically induced FA alterations (Figure 10A) were 
quantified along the segmented WM tracts of infected animals (17.6% reduction vs. control 
group: see Figure 9C; control 0.69±0.07, infected 0.57±0.05; normalized values ranging from 
0 to 1) and in the SSC (36% reduction vs. control group: see Figure 9C; control 0.25±0.03, 
infected 0.16±0.04; normalized values ranging from 0 to 1). Within the entire GM area no 
significant FA reduction could be assessed. 
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Figure 9. In vivo DT-MRI based quantitative evaluation of brain microstructural alterations induced by 
chronic T. gondii infection 
(A) Group averaged (control vs. T. gondii) coronal fiber density (FD) maps, generated after spatial normalization 
to a mouse brain template, show a general pattern of fiber loss particularly evident in white matter areas (arrows, 
cg - cingulum; cc – corpus callosum; ic – internal capsule) of T. gondii infected mice. The FD values were 
normalized from 0 (no fibers mapped) to 1 (maximum density of fibers depicted in averaged FD maps across the 
whole population of investigated animals).  
(B, C) Quantitative comparison of the FD and fractional anisotropy (FA) values in white matter (WM), gray 
matter (GM) and the somatosensory cortex (SSC) of control and T. gondii infected animals. Note the significant 
reduction of FD and FA in WM and SSC brain areas upon chronic T. gondii infection. Lower FD and FA values 
were quantified within the GM brain area, without reaching the threshold of statistical significance.  
(D) Maps illustrate the brain masks (WM – dark area; GM – white area; and SSC) used for the quantitative 
analysis presented in B and C. The WM and GM masks were generated after segmentation of spatially 
normalized and averaged T2-weighted images.  All data are expressed as mean±SEM, T. gondii infected mice 
n=7, control mice n=9.*p<0.05; ns, not significant. 
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4. Neuroinfection is associated with white matter microstructural 
abnormalities 
Interestingly, probing the WM microstructure with electron microscopy revealed myelin 
abnormalities in the T. gondii infected brains (Figure 10B). Particularly, we could identify 
numerous axons displaying clear decompaction and degeneration of the myelin lamellae 
(Figure 10B, arrows, against the normal myelination pattern indicated by arrowheads). Such 
features are generally considered specific hallmarks of the WM pathology.  
Moreover, quantification of D┴ values in the WM of infected mice evidenced a statistically 
significant elevation of the water diffusivity perpendicular to the fiber tracts (Figure 10C; 
control 0.47±0.08 mm²/s, infected 0.58±0.07 mm²/s). Increased values of D┴ were previously 
associated with myelin degeneration (239,250,251), suggesting that chronic T. gondii 
infection could elicit pathological processes leading to myelin sheath alterations and 
consequently, disrupted structural connectivity. Although subtle modifications of the <D> and 
D║ were also noticed in the WM, GM and the SSC of T. gondii infected brains (Figure 10C), 
these parameters do not show enough sensitivity for discriminating the structural 
modifications induced by the pathology.  
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Figure 10. Quantitative assessment of modifications induced by T. gondii infection on brain parametric 
maps generated from in vivo DT-MRI data 
(A) Comparison of group averaged coronal FA maps (control vs. T. gondii infected groups) within two different 
brain locations, showing decreased FA values along the WM tracts (i.e. cc – corpus callosum; ec – external 
capsule; fx – fornix). 
(B) Electron micrographs from T. gondii infected brain, depicting axons with myelin lamellae decompaction (left 
panel – arrows). Intact myelin sheath surrounding healthy axons are comparatively shown in the right panel – 
arrowheads.  
(C) Detailed quantitative comparison of mean (<D>), radial (D┴) and axial (D║) diffusivities in white matter 
(WM), gray matter (GM) and somatosensory cortex (SSC) of control and T. gondii infected animals. D┴ is the 
only parameter showing statistically significant increase in the WM of infected brains. Note also the general 
trend of elevated mean diffusivity <D> in all investigated regions of interest (ROIs). All data are expressed as 
mean±SEM, T. gondii infected mice n=7, control mice n=9. *p<0.05; ns, not significant 
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5. Chronic infection is negatively influencing the dendritic morphology of 
noninfected cortical neurons  
In view of the alterations observed throughout the brains of mice infected with T. gondii, we 
next performed a detailed analysis of the dendritic morphology of individual neurons within 
different brain regions. Specifically, we selected Layer II/III pyramidal neurons from the 
cortex, a brain region where we have previously identified microstructural alterations. When 
qualitatively compared to control Layer II/III pyramidal neurons, the cells derived from 
infected mice showed a very simplified dendritic tree (Figure 11A). This pattern was 
confirmed by comparing the total dendritic length (Figure 11B, B’) and total dendritic 
complexity (Figure 11D, D’) using the Sholl analysis.  
In view of their different morphology and connectivity, we analyzed the complexity of apical 
and basal dendrites separately. Total dendritic length of layer II/III neurons of T. gondii 
infected mice was reduced both for the apical and the basal dendrites (Figure 11B: control 
basal n=16, 1872.45±167.95 µm, infected basal n=16, 1357.41±104.17 µm, 27.5% reduction; 
Figure 11B’: control apical n=20, 1228.36±102.84 µm, infected apical n=20, 1059.74±92.42 
µm, 13.72% reduction).  
Moreover, a statistically significant reduction in total dendritic complexity for the basal 
dendritic compartment was observed in infected vs. control mice (Figure 11D: control basal 
n=16, 161.38±15.11 intersections, infected basal n=16, 124.31±8.99 intersections, 22.97% 
reduction; Figure 11D’: control apical n=20, 99.15±8.2 intersections, infected apical n=20, 
86.5±8 intersections, 12.75% reduction).  
A more detailed Sholl analysis performed by plotting the number of intersections against the 
distance from the cell body confirmed these results (Figure 11C) and revealed a significant 
decrease in complexity of the basal [110 µm radius (control, 9.63±1.39; infected 6.19±0.83; 
p=0.04), 120 µm radius (control, 8.19±1.3; infected 4.75±0.82; p=0.03), 130 µm radius 
(control, 6.69±1.31; infected 3.38±0.6; p=0.02), 140 µm radius (control, 5.25±1.09; infected 
2.5±0.56; p=0.03)] but not for the apical dendrites in layer II/III cells of T. gondii infected 
mice. 
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Figure 11. Morphological analysis of Layer II/III pyramidal neurons within the cortices of T. gondii 
infected and control mice 
(A) Shows two examples of rendered pyramidal neurons, consisting of stacks of multiple optical sections from 
control and T. gondii infected mice. Note the simplified dendritic architecture of the neuron from the T. gondii 
infected brain. Scale bar is 100µm. (B, B’), the graphs compare total dendritic length for the basal (B) and apical 
(B’) dendritic tree in neurons of control vs. infected mouse brain. (C), Sholl analysis, plotting dendritic 
complexity in relation to the distance from the cell body for the basal (left) and apical (right) dendrites of Layer 
II/III neurons of control and infected mouse brain. (D, D’), the graphs show the total dendritic complexity for the 
basal (D) and apical (D’) dendritic tree of Layer II/III neurons of control and infected mouse brain. Analysis was 
performed in three independent experiments. All data are expressed as mean±SEM, n=3-4 mice per 
group.*p<0.05; ns, not significant 
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6. Dendritic spine density and morphology is affected in the cortex of 
infected mice 
Changes in dendritic morphology indicate changes in the number and morphology of 
dendritic spines, which are responsible for the inter-neuronal information exchange. Apical 
and basal dendrites were visualized by the expression of Dil stain in a random population of 
cortical pyramidal neurons of infected and noninfected brains. When Dil dye-expressing 
dendrites were qualitatively compared, a clear alteration in the number of dendritic spines 
could be detected (Figure 12A-D). Additionally, the density of dendritic spines was 
quantitatively analyzed both for the apical and basal dendrites in layer II/III neurons of 
infected mice and showed a significant reduction when compared to neurons from the same 
area of control mice (Figure 12E: control apical n=24, 1.47±0.06 spines/µm, infected apical 
n=20, 1.16±0.11 spines/µm; Figure 12F: control basal n=23, 1.53±0.04 spines/µm, infected 
basal n=19, 1.15±0.09 spines/µm). 
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Figure 12. Spine density deficits in pyramidal neurons within the cortex of T. gondii infected mice 
(A and B) Representative confocal high-magnification images of apical (A) and basal (B) dendrite branches from 
pyramidal neurons of noninfected mouse brain. (C and D) Representative high-magnification images of apical 
(C) and basal (D) dendrite branches from pyramidal neurons of infected mouse brain. Note the reduced density 
of dendritic spines. Scale bar is 10 μm. (E and F) Spine density counts showing a significantly lower spine 
density in both apical (E) and basal (F) dendritic compartments from cortical pyramidal neurons of T. gondii 
infected mouse brain. Analysis was performed in three independent experiments. All data are expressed as 
mean±SEM, n=3-4 mice per group. **p<0.01 
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Finally, in order to detect possible changes in the morphology of dendritic spines their length 
and head width were compared in pyramidal neurons of control vs. infected mice. The length 
was measured from their base at the dendrite to the tip of their head. Interestingly, spine 
length and spine head width showed a significant reduction for the apical dendrites (Figure 
13A: control apical n=11, 1.53±0.01 µm, infected apical n=8, 1.27±0.08 µm; p=0.002; 
Figure13C: control apical n=11, 0.85±0.02 µm, infected apical n=8, 0.76±0.02 µm; p=0.03) 
while the morphology of the spines on the basal dendrites was not altered (Figure 13B: 
control basal n=7, 1.436±0.126 µm, infected basal n=6, 1.204±0.08 µm; p=0.1; Figure 13D: 
control basal n=7, 0.84±0.05 µm, infected basal n=6, 0.79±0.07 µm; p=0.5). 
 
 
Figure 13. Effect of infection with T. gondii on cortical dendrites spine length and spine head width 
Comparative analysis of dendritic spine length and spine head morphology of apical (A, C) and basal (B, D) 
dendrites from pyramidal neurons of control and T. gondii infected mouse brain is shown. Chronic infection 
triggers a significant reduction in the spine length and spine head width for the apical dendrites, but not for the 
basal dendrites. The length was measured from the base of the dendrite to the tip of their head. Analysis was 
performed in three independent experiments. All data are expressed as mean±SEM, n=3-4 mice per group. 
**p<0.01; ns, not significant 
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7. Chronic infection with T. gondii alters the structure of hippocampal 
neurons  
In addition to the Layer II/III pyramidal neurons from the cortex, we next focused our 
analysis on hippocampus, a key neuroanatomical structure highly relevant to normal behavior, 
cognition and memory. Thus, we performed a detailed analysis of the dendritic morphology of 
individual granule cells of the dentate gyrus (DG) as well as CA1 pyramidal neurons from the 
hippocampus. Qualitative comparison between DG granule neurons revealed that the cells 
derived from infected mice showed a subtle reduction in the dendritic tree (Figure 14A). The 
reduction was further confirmed by comparing the total dendritic length (Figure 14B; control 
n=35, 890.7±46 µm, infected n=30, 742.5±42 µm, 16.6% reduction). Moreover, detailed 
Sholl analysis, performed in the DG granule cells of infected mice showed a clear reduction in 
dendritic complexity (intersections) (Figure 14C) throughout the entire dendritic length (160 
µm from the cell body) with statistical significance for the 20 µm (control, 2.72±0.75; 
infected, 2.0±0.21; p=0.02), 70 µm (control, 6.67±0.91; infected, 5.27±0.31; p=0.006), 150 
µm (control, 5.31±0.84; infected, 4.0±0.46; p=0.03) and 160 µm (control, 4.69±0.86; 
infected, 3.5±0.43; p=0.04) radius. Total dendritic complexity (intersections) indicated a 
significant reduction of dendritic arbor in granule cells of the DG (Figure 14D; control n=35, 
84.81±4.39 intersections; infected n=30, 70.03±4.36 intersections, 17.42% reduction).  
Once more, given their different structure and connectivity, we analyzed the complexity of 
CA1 apical and basal dendrites separately. Total dendritic length of CA1 neurons of T. gondii 
infected mice was reduced both for the apical and the basal dendrites (Figure 15A, B; control 
apical n=15, 1744.5±169.1 µm, infected apical n=12, 1359.1±119.1 µm; control basal n=12, 
1514.7±172.9 µm, infected basal n=11, 1111.2±148.3 µm). Similarly, the Sholl analysis 
revealed a decrease in complexity of the apical and basal dendrites of CA1 pyramidal neurons 
of infected vs. control mice, throughout the analyzed length (Figure 15C) with the following 
statistical significances for apical [50 µm radius (control, 6.93±0.91; infected 4.25±0.57; 
p=0.03), 100 µm radius (control, 10.4±0.93; infected 7.83±0.6; p=0.04), 110 µm radius 
(control, 10.73±0.95; infected 7.5±0.52; p=0.01), 120 µm radius (control, 10.13±0.79; 
infected 7.5±0.78; p=0.03), 140 µm radius (control, 9±0.94; infected 5.92±0.75; p=0.02), 150 
µm radius (control, 8.47±1.05; infected 5.42±0.79; p=0.04)] and basal [50 µm radius (control, 
14.08±1.05; infected 9.36±1.25; p=0.008), 60 µm radius (control, 14.58±1.36; infected 
9.45±0.99; p=0.007), 70 µm radius (control, 14.17±1.72; infected 9.18±0.98; p=0.02), 80 µm 
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radius (control, 13.92±1.72; infected 8.73±1.32; p=0.02), 90 µm radius (control, 13±1.82; 
infected 8.09±1.44; p=0.04)] dendrites. Comparing total dendritic complexity of CA1 
pyramidal neurons showed a clear reduction upon T. gondii infection for both apical and basal 
dendritic branches (Figure 15D, E; basal, control n=13, 141.58±14.53 intersections; infected 
n=15, 99.45±12.97 intersections, 29.76% reduction; apical, control n=13, 128.53±11.21 
intersections; infected n=15, 95.17±0.8 intersections, 25.96% reduction).  
 
Figure 14. Morphological investigation of granule neurons within dentate gyrus of T. gondii infected and 
control mice 
(A) Neurolucida reconstruction of DG neurons, consisting of stacks of multiple optical sections from control and 
T. gondii infected mice. Note the simplified dendritic architecture of the neuron from the T. gondii infected 
brain. Scale bar is 50µm. (B) The graph compares total dendritic length of the dendritic tree in neurons of control 
vs. infected mouse brain. (C) Sholl analysis, plotting the distribution of dendritic complexity in relation to the 
distance from the cell body of neurons from the dentate gyrus of control and T. gondii infected mice. (D) The 
graph shows the total dendritic complexity (intersections) for the dendritic tree of granule neurons in the dentate 
gyrus of control and infected brains. Analysis was performed in three independent experiments. All data are 
expressed as mean±SEM, n=3-4 mice per group.*p<0.05; **p<0.01 
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Figure 15. Morphological analysis of neurons within CA1 pyramidal neurons of T. gondii infected and 
control mice 
(A and B) The graph shows the total dendritic length for the basal (A) and apical (B) dendritic tree of CA1 
neurons of control and infected mouse brain.  (C) Sholl analysis, plotting the distribution of dendritic complexity 
in relation to the distance from the cell body for the basal (left) and apical (right) dendrites of CA1 pyramidal 
neurons of control and T. gondii infected brain. (D and E) the graphs show the total dendritic complexity 
(intersections) for the basal (D) and apical (E) dendritic tree of CA1 pyramidal neurons of control and T. gondii 
infected brain. Analysis was performed in three independent experiments. All data are expressed as mean±SEM, 
n=3-4 mice per group.*p<0.05; **p<0.01.  
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8. Synaptophysin and PSD95 protein expression level is reduced in the 
cortex and the hippocampus of mice chronically infected with T. gondii 
To determine whether the observed changes in neuronal architecture might be reflected in 
altered expression of key molecules involved in synaptic signaling, we investigated the 
expression of presynaptic synaptophysin as well as the postsynaptic density protein (PSD95) 
by western immunobloting. Semi-quantitative protein expression revealed significantly lower 
protein levels of these two molecules between T. gondii infected and noninfected animals, in 
both cortex and hippocampus (Figure 16A, B; relative intensities normalized to GAPDH: 
PSD95, cortex: control animals, 0.88±0.05; infected mice, 0.69±0.03; p=0.01; PSD95, 
hippocampus: control animals, 0.91±0.03; infected mice, 0.73±0.02; p=0.005; Synaptophysin, 
cortex: control animals, 1.06±0.04; infected mice, 0.69±0.12; p=0.03; Synaptophysin, 
hippocampus: control animals, 1.11±0.07; infected mice, 0.73±0.07; p=0.01; unpaired 
Student’s t test). Our findings provide evidence that chronic T. gondii infection can interfere 
with the normal activity of mature synapses in key brain structures. 
 
Figure 16. Impaired expression of synaptic related proteins in T. gondii infected brains 
(A) Representative blots from the cortex and hippocampus whole tissue extracts of control and T. gondii infected 
mice, used for PSD95 and Synaptophysin protein semi-quantification. (B) Densitometric analysis of PSD95 and 
Synaptophysin protein levels revealed statistically significant reductions in T. gondii infected mice, suggesting 
deficits of the synaptic cleft physiology. Analysis was performed in three independent experiments. Data are 
expressed as mean±SEM, n=3-4 mice per group. *p<0.05 and ** p<0.01. 
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9. Latent infection with T. gondii alters the proteome of adult mouse 
cortical and hippocampal synaptosomes 
Synapses provide the physical basis for communication within the brain, and the ability for 
synapses to maintain their integrity and functionality is critical to maintaining proper CNS 
function. Quantitative proteomic analysis is a useful heuristic tool to analyze global changes 
in expression of synaptic proteins in several animal models of neurological and 
neuropsychiatric illness (252–255). In the present study we employed this approach to 
demonstrate differentially expressed proteins critical for signaling at synapses of mice 
chronically infected with T. gondii. For that, we performed a subcellular fractionation 
protocol (244) to obtain synaptosomes which contain both pre- and post-synaptic 
compartments, from cortex and hippocampus of control and infected mice.  
The results presented here are preliminary, obtained from a limited number of biological 
replicates, and ongoing experiments will confirm and further expand these findings. 
Two biological replicates of control and infected mice were used in iTRAQ experiments 
(254), in which we identified more than 800 unique proteins. Further analysis focused on 
characterization of strongly deviating protein levels and resulted in 120 identified proteins 
differentially regulated (see annex), which were functionally mapped by IPA software. 
Initially, we used IPA to identify behavioral and neurological disorders associated with 
differentially expressed synaptic proteins in infected mice. Among these, the main 
neurobehavioral disorders include memory, learning, locomotion, social interactions, 
cognitive impairment, schizophrenia, Alzheimer’s disease, mental retardation (Table 2 and 
Table 3).  
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Table 2. Behavioral dysfunctions associated with altered proteins in chronically infected mice 
synaptosomes. P-values were determined by Fisher's exact test 
 
 
 
 
 
 
 
 
 
 Function p-Value Molecules # 
B
eh
a
v
io
r 
working 
memory 
3.82E-03 HOMER1, SYNGAP1 2 
spatial 
memory 
3.41E-04 APOD, GRIA2, HOMER1, LRRC7, SYNGAP1 5 
short-term 
memory 
4.53E-04 HOMER1, LRRC7, SYNGAP1 3 
spatial 
learning 
1.25E-04 APOD, APOE, GRIN1, PLCB1, PPP1R1B, Ptprd, SYNGAP1 7 
learning 9.97E-08 
APOD, APOE, DLG4, GABBR2, GABRA1, GRIA2, GRIN1, HOMER1, LRRC7, PLCB1, 
PPP1R1B, PPT1, SLC12A5, SYNGAP1 
14 
exploratory 
behavior 
2.05E-03 APOE, GRIA2, RIMS1, SYNGAP1 4 
locomotion 4.77E-08 
APOE, DLG4, GABRA1, GRIA2, GRIA3, GRIN1, HOMER1, LRRC7, PCSK1N, 
PPP1R1B, PPT1, RIMS1, RTN4, SLC17A6 
14 
hyper 
locomotion 
2.51E-03 DLG4, SLC17A6 2 
social 
behavior 
8.68E-05 GRIN1, GSTM5, RIMS1, RTN4, SYNGAP1 5 
social 
withdrawal 
2.51E-03 RTN4, SYNGAP1 2 
anxiety 1.22E-03 APOE, GABBR2, HOMER1, LRRC7, PCSK1N, SYNGAP1 6 
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Table 3. Neurological dysfunctions associated with altered proteins in chronically infected mice 
synaptosomes. P-values were determined by Fisher's exact test 
 
 
 
 
 
 
 
 
Function p-Value Molecules # 
N
eu
ro
lo
g
ic
a
l 
D
is
o
rd
er
s 
movement 
disorders 
1.93E-15 
APOD, APOE, ARHGDIB, ATCAY, B2M, BCAS1, C4A/C4B, CHGA, CHGB, CLU, 
CTSD, DLG2, DNAJC5, GABBR2, GABRA1, GFAP, GRIA2, GRIA3, GRIN1, 
HOMER1, LAMP2, MAL2, NDUFB5, PFN1, PLCB1, PPP1R1B, PPT1, PRDX6, 
PVALB, RAB3A, RHOG, RTN4, SCG2, SLC1A2, SV2A, SYNGAP1, TPM3 
37 
seizure disorder 1.86E-12 
CHGB, CLU, CTSD, GABBR2, GABRA1, GFAP, GRIA2, GRIN1, HOMER1, LGI1, 
NAMPT, PLCB1, PPP1R1B, PPT1, RIMS1, SG, SLC12A5, SLC1A2, SLC6A11, 
SV2A, SV2B, SYNGAP1 
22 
Alzheimer's 
disease 
5.54E-12 
ACLY, ALB, APOD, APOE, C4A/C4B, CLU, CST3, CTSD, GABBR2, GABRA1, 
GFAP, GRIA2, GRIA3, GRIN1, HOMER1, LGAS, PRDX1, PRKACA, RIMS1, 
SLC1A2, SV2A, SYP, TF 
23 
schizophrenia 1.57E-11 
APOD, APOE, C4A/C4B, CHGB, DLG2, DLG4, GABRA1, GFAP, GRIN1, 
HOMER1, LGALS1, LGI1, PPP1R1B, PRDX6, PVALB, RTN4, S100A6, SCG2, 
SLC12A5, SLC1A2, SYP, TF 
22 
Huntington's 
Disease 
4.42E-11 
APOD, APOE, B2M, C4A/C4B, CHGB, CLU, GABRA1, GFAP, GRIN1, HOMER1, 
LAMP2, MAL2, NDUFB5, PFN1, PLCB1, PPP1R1B, PRDX6, PVALB, RAB3A, 
RHOG, SCG2, SLC1A2, TPM3 
23 
epilepsy 1.85E-09 
CHGB, CLU, GABRA1, GFAP, GRIN1, HOMER1, LGI1, NAMPT, PLCB1, 
PPP1R1B, SCG2, SLC12A5, SLC1A2, SLC6A11, SV2A 
15 
major 
depression 
2.60E-05 APOE, CHGA, GABRA1, GFAP, GRIA3, GRIN1, KRT17, WFS1 8 
cognitive 
impairment 
3.59E-05 
APOE, CST3, GABBR2, GABRA1, GRIA3, GRIN1, HOMER1, SLC1A2, 
SYNGAP1, SYP 
10 
bipolar disorder 4.67E-05 APOD, APOE, DLG4, GABRA1, GRIA2, GRIA3, GRIN1, HSP90B1, PRDX1, WFS1 10 
Neuroinflamm. 
of brain 
4.96E-04 GFAP, PPT1 2 
mental 
retardation 
2.10E-03 GABBR2, GRIA3, GRIN1, SLC1A2, SYNGAP1, SYP 6 
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Next, we could categorically organize proteins into functional pathways. Comparison analysis 
revealed alterations of the glutamate signaling canonical pathway, which is relevant for 
normal functioning of the synapse (Figure 17). 
 
 
Figure 17. Canonical pathway with reduced activity implicates glutamatergic signaling 
Protein clustering was performed with Ingenuity Pathway Analysis (IPA, Ingenuity Systems) based on molecular 
functions, cellular functions and functional group. Data show proteins with decreased level (green) and increased 
level (red). Straight lines indicate direct interactions while dashed lined stand for regulatory effects. 
Abbreviations: ACLY, ATP citrate lyase; Akt, protein kinase B; ANKS1B, ankyrin repeat and sterile alpha motif 
domain containing 1B; CHGA, chromogranin A; CHGB, chromogranin B; DLG4, disks, large homolog 4 
(PSD95); DNAJC5, DnaJ homolog, subfamily C, member 5; GBP2, guanylate binding protein 2, interferon-
inducible; GRIN1, glutamate receptor, ionotropic (NR1); GRIA2, glutamate receptor, ionotropic (AMPA2); 
GRIA3, glutamate receptor, ionotropic (AMPA3); HOMER1, homer homolog 1; LCP1, lymphocyte cytosolic 
protein 1; LRRC7, leucine rich repeat containing 7; PPP1R1B, protein phosphatase 1, regulatory subunit 1B; 
PPT1, palmitoyl-protein thioesterase 1; PRKACA, protein kinase, cAMP-dependent, catalytic, alpha; PVALB, 
parvalbumin; RAB3A, member RAS oncogene family; RAB3B, member RAS oncogene family; RIMS1, 
regulating synaptic membrane exocytosis 1; SLC4A4, solute carrier family 4, member 4; SYNGAP1, synaptic 
Ras GTPase activating protein 1; SYNGR3, synaptogyrin 3; SYP, synaptophysin;  
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A global inspection of regulatory data from control and infected samples was performed by 
box plot analysis (Figure18A). Protein regulation factors in assessed samples indicated a wide 
regulation range from +2.9 to -1.3 (log2RF= log2 regulation factor) (Figure18A). Moreover, 
from the 120 proteins differentially regulated we have selected and focused our analysis on 25 
proteins strongly deviating upon infection with T. gondii, and which might be of clinical 
interest for future studies (Table 4). The regulation factors of a selection of proteins that might 
be of clinical interest are presented as heat maps (Figure 18B). 
In conclusion, synaptosomes isolated from infected mice show altered expression of synaptic 
proteins-mediated cellular signaling, supporting the hypothesis that persistent infection with 
T. gondii impacts on the synaptic efficacy, which likely cause neurobehavioral abnormalities. 
Importantly, it is an exploratory study that forms the bases for further targeted investigations. 
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Figure 18. Statistical evaluation of synaptosome protein data 
(A) Box plot of protein regulation factors in control and infected cortical and hippocampal synaptosomes 
determined by iTRAQ-based LC-MS/MS quantitation. Each box displays 50% of all determined protein 
regulation factors, the box height depicts their spreading and the black line within the boxes indicated the 
median. The restricting lines (high and low whiskers) display 1.5 X height of the box. All protein regulation 
factors above or beneath the whiskers are categorized as strongly regulated and are shown as open dots. (B) Heat 
map of log2-protein regulation factors of 25 selected candidates, with significant reduced levels. Heat maps were 
generated by loading the list of selected proteins into the statistical program R. Colored boxes display the 
regulation factors corresponding to the indicated color code (top). 
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UniProt 
accession 
name 
UniProt 
accession 
number 
Protein name Biological functions Pathology References 
ATCAY Q8BHE3 
 
Caytaxin Regulates glutaminase, the 
enzyme responsible for glutamate 
production by neurons 
Jittery phenotype, which is 
characterized by severe 
truncal and limb ataxia 
(256) 
BSN O88737 Protein Bassoon Neurotransmitter release in brain 
glutamatergic synapses 
Altered excitability attributed 
to inactivation of brain 
glutamatergic synapses. 
(257) 
DLG2 Q91XM9 Disk large 
homolog 2 
Part of the postsynaptic protein 
scaffold of excitatory synapses, 
regulates surface expression of 
NMDA receptors 
Reduced response to 
persistent pain. Postsynaptic 
surface expression of NMDA 
receptors and NMDA 
receptor-mediated synaptic 
function are reduced. 
(258) 
DLG4 Q62108 Disk large 
homolog 4 (PSD-
95) 
Required for synaptic plasticity 
associated with NMDA receptor 
signaling. 
Impaired spatial learning, 
altered NMDA-mediated 
synaptic plasticity. 
(259) 
EAA2 P43006 Excitatory 
amino-acid 
transporter 2 
Transport of L-glutamate, 
glutamate re-uptake from the 
synaptic cleft. 
- - 
GABR2 Q80T41 γ-aminobutyric 
acid type B 
receptor subunit 2 
Component of G-protein coupled 
receptor for GABA, implicated in 
synaptic inhibition but also in 
hippocampal long-term 
potentiation 
- - 
GBRA1 P62812 γ-aminobutyric 
acid receptor 
subunit alpha-1 
Component of the receptor for 
GABA. 
- - 
GLNA P15105 Glutamine 
synthetase 
Catalyzes the production of 
glutamine and γ-aminobutyric 
acid. 
- - 
GLSK D3Z7P3 Glutaminase 
kidney isoform, 
mitochondrial 
Regulates the levels of the 
neurotransmitter glutamate in the 
brain. 
Normal levels of activity but 
disorganized. 
(260) 
GRIA2 P23819 Glutamate 
receptor 2 
(AMPA2) 
Receptor for glutamate that 
functions as ligand-gated ion 
channel in the CNS, key role in 
excitatory synaptic transmission. 
- - 
GRIA3 Q9Z2W9 Glutamate 
receptor 3 
(AMPA3) 
Receptor for glutamate that 
functions as ligand-gated ion 
channel in the CNS, key role in 
excitatory synaptic transmission. 
- - 
HOME1 Q9Z2Y3 Homer protein 
homolog 1 
Postsynaptic density scaffolding 
protein. 
- - 
KCD16 Q5DTY9 BTB/POZ 
domain-
containing 
protein KCTD16 
Auxiliary subunit of GABA-B 
receptors that determine the 
pharmacology and kinetics of the 
receptor response. 
 (261) 
NMDE1 P35436 Glutamate 
receptor 
ionotropic, 
NMDA 2A 
NMDA receptor subtype of 
glutamate-gated ion channels. 
- - 
NMDE2 Q01097 Glutamate 
receptor 
ionotropic, 
NMDA 2B 
NMDA receptor subtype of 
glutamate-gated ion channels. 
- (262) 
NMDZ1 P35438 Glutamate 
receptor 
ionotropic, 
NMDA 1 
NMDA receptor subtype of 
glutamate-gated ion channels. 
Key role in synaptic plasticity, 
synaptogenesis, excitotoxicity, 
memory acquisition and learning. 
- - 
NPTN P97300 Neuroplastin Cell adhesion molecule involved 
in long term potentiation at 
hippocampal excitatory synapses, 
role in synaptic plasticity 
- - 
PCLO Q9QYX7 Protein piccolo Scaffolding protein involved in 
the organization of synaptic 
active zones and in synaptic 
vesicle trafficking 
- (263) 
RAB3B Q9CZT8 Ras-related 
protein Rab-3B 
Protein transport. Probably 
involved in vesicular traffic 
- - 
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UniProt 
accession 
name 
UniProt 
accession 
number 
Protein name Biological functions Pathology References 
RIMS1 Q99NE5 Regulating 
synaptic 
membrane 
exocytosis 
protein 1 
Essential for maintaining normal 
neurotransmitter release and for 
regulating release during short-
term synaptic plasticity. 
- - 
SNG3 Q8R191 Synaptogyrin-3 Positive regulation of dopamine 
transporter activity 
- - 
SV2A Q9JIS5 Synaptic vesicle 
glycoprotein 2A 
Regulates neurotransmitter 
vesicle fusion by maintaining the 
readily releasable pool of 
secretory vesicles 
Severe epileptic seizures (264) 
SV2B Q8BG39 Synaptic vesicle 
glycoprotein 2B 
Role in the control of regulated 
secretion in neural and endocrine 
cells. 
Severe epileptic seizures (265) 
SYPH Q62277 Synaptophysin Regulation of short-term and 
long-term synaptic plasticity 
Impaired short-term and long-
term synaptic plasticity 
(266) 
VGLU2 Q8BLE7 Vesicular 
glutamate 
transporter 2 
Mediates the uptake of glutamate 
into synaptic vesicles at 
presynaptic nerve terminals of 
excitatory neural cells. 
Reduction in evoked 
glutamergic responses 
(267) 
 
Table 4. Summary of proteins strongly downregulated during chronic cerebral infection with T. gondii 
List of 25 identified proteins with decreased level in the synaptosomes. Included are the UniProt 
(http://www.uniprot.org/) accession names and numbers, protein names as well as the biological functions and 
reported involvement in pathology. 
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10. Glutamate receptor abnormalities in the synapses of infected mice  
Previous reports have shown that synaptic dysfunction can be a consequence of prolonged 
neuroinflammation, suggesting that inflammatory processes modulate the changes from 
physiological synaptic transmission to impaired functioning (213,214,218). In the CNS, 
glutamate receptors are synaptic receptors important for neural communication, memory 
formation, learning, and regulation (268,269). Altered glutamate AMPA and NMDA 
ionotropic receptor function/presence have been showed to contribute to a variety of 
neurological and neuropsychiatric conditions (270–272). To determine whether T. gondii 
infection induces synaptic dysfunctions due to glutamate subunit expression alterations, we 
compared the expression level of the NMDA receptor subunits NR1, NR2A and NR2B, as 
well as AMPA receptor subunits AMPA1 and AMPA2, in cortical and hippocampal synaptic 
junction fractions of chronically infected mice and noninfected littermates. 
 
Western blot analysis revealed that protein expression levels of AMPA 1 and 2 subunits was 
not significantly altered between groups (Figure 19A, B; relative intensities normalized to 
GAPDH: AMPA1, cortex: control animals, 1.328±0.18; infected mice, 1.605±0.16; p=0.2; 
AMPA1, hippocampus: control animals, 0.915±0.05; infected mice, 0.856±0.06; p=0.5; 
AMPA2, cortex: control animals, 0.98±0.16; infected mice, 0.702±0.06; p=0.1; AMPA2, 
hippocampus: control animals, 1.258±0.2; infected mice, 1.439±0.29; p=0.6; unpaired 
Student’s t test).  
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Figure 19. The expression of glutamate receptor subunits AMPA1 and AMPA2 is not altered by chronic 
infection with T. gondii 
(A) Representative blots from the cortex and hippocampus synaptic junction fractions of control and T. gondii 
infected mice, used for the quantification of glutamatergic receptor subunits AMPA1 and AMPA2 protein level. 
(B) Densitometric analysis of AMPA1 and AMPA2 protein levels revealed no significant change in T. gondii 
infected mice when compared with controls. Analysis was performed in two independent experiments. Data are 
expressed as mean±SEM, n=3-4 mice per group. n.s, not significant 
 
Interestingly, in contrast to AMPA receptor subunits, protein expresion levels of NMDA  
subunits NR1, NR2A and the NR2B were significantly decreased in the synaptic junction 
fraction of infected mice (Figure 20A, B; relative intensities normalized to GAPDH: NR1, 
cortex: control animals, 1.195±0.07; infected mice, 0.664±0.06; p=0.0002; NR1, 
hippocampus: control animals, 1.215±0.10; infected mice, 0.695±0.09; p=0.003; NR2A, 
cortex: control animals, 0.938±0.05; infected mice, 0.323±0.04; p<0.0001; NR2A, 
hippocampus: control animals, 1.015±0.03; infected mice, 0.3688±0.07; p<0.0001; NR2B, 
cortex: control animals, 1.055±0.09; infected mice, 0.665±0.06; p=0.005; NR2B, 
hippocampus: control animals, 0.969±0.04; infected mice, 0.608±0.08; p=0.004; unpaired 
Student’s t test), although the effect on NR2A levels appeared to be greater.  
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Figure 20. Chronic infection with T. gondii is associated with NMDA receptor subunit abnormalities 
(A) Representative blots from the cortex and hippocampus synaptic junction fractions of control and T. gondii 
infected mice, used for the quantification of glutamatergic receptor subunits NR1, NR2A and NR2B protein 
level. Particularly, the levels of NR2A appear highly reduced in synaptic junctions of infected mice, in both 
cortex and hippocampus. (B) Quantification of NR1, NR2A and NR2B protein levels confirmed the significant 
reduction in mice infected with T. gondii, suggesting synapse dysfunction. Analysis was performed in two 
independent experiments. Data are expressed as mean±SEM, n=3-4 mice per group. **p<0.01, *** p<0.001, 
**** p<0.0001 
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11. Akt/GSK3β signaling defects in the cortex of chronically infected mice 
Proteomic analysis of the synaptosome fraction revealed that chronic infection of the nervous 
system is associated with alterations of the Akt dependent signaling pathway (Figure 17). The 
Akt signaling pathway is a major upstream signaling regulator of GSK3β. It is activated upon 
phosphorylation at threonine (Thr308) and serine (Ser473) residues, and once active 
phosphorylates downstream targets such as GSK3β (273–275). Akt/GSK3β pathway regulates 
multiple substrates, including metabolic, signaling, and structural proteins and transcription 
factors (274,275). It has been hypothesized that impaired Akt/GSK3β signaling may provide 
an important molecular mechanism contributing to the pathology of neuropsychiatric illnesses 
(273–275), therefore we sought evidence for the presence of molecular and functional 
changes in the AKT/GSK3β pathway. 
First, we explored the effects of T. gondii induced neuroinflammation on cortical Akt protein 
expression and phosphorylation using western blot analyses. We found that chronic infection 
with T. gondii results in increased levels of Akt phosphorylation on threonine 308 and serine 
473 sites, in whole cortex homogenates (Figure 21C, D, relative intensities normalized to 
GAPDH: pAkt (Ser473), control mice 0.587±0.13; infected mice 1.753±0.06; p=0.0002; pAkt 
(Thr308), control mice 1.356±0.16; infected mice 2.212±0.14; p=0.01; unpaired Student’s t 
test). In contrast to these effects, the infection and neuroimmune activation did not 
signiﬁcantly alter the expression of total Akt in the cortex (Figure 21A, B, relative intensities 
normalized to GAPDH: control mice 1.085±0.03; infected mice 1.007±0.07; p=0.4; unpaired 
Student’s t test).  
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Figure 21. Effects of T. gondii induced neuroinflammation on Akt expression and phosphorylation 
(A) Western blot analysis of total Akt (pan), phosphorylated Akt (Ser473) or Akt (Thr308) levels in extracts 
prepared from cortex homogenates of control and chronically infected mice. GAPDH was used as a loading 
control. (B-D) Densitometric analysis of Akt (B), pAkt (Ser473) (C), and pAkt (Thr308) (D) revealed that 
chronic toxoplasmosis is associated with a strong activation of Akt protein kinase as indicated by the significant 
increase of both phosphorylated Akt protein levels. Analysis was performed in two independent experiments. 
Data are expressed as mean±SEM, n=4-5 mice per group. *p<0.05, ***p<0.001, n.s, not significant 
 
In the next step, we evaluated the effects of chronic neuroinflammation on the expression of 
total and phosphorylated GSK3β, in the cortex, by measuring the mRNA and protein levels. 
As shown in Figure 22A, the samples from infected mice did not show a statistical difference 
in the GSK3β mRNA levels as compared to controls (control mice 0.126±0.002; infected 
mice 0.119±0.002; p=0.3; unpaired Student’s t test). In line with this result, no signiﬁcant 
group differences were found with respect to the total GSK3β protein levels (Figure 22B, C, 
relative intensities normalized to GAPDH: control mice 0.982±0.1; infected mice 0.848±0.04; 
p=0.2; unpaired Student’s t test). However, an additional analysis of the phosphorylated 
GSK3β protein demonstrated a statistically significant increase in the relative GSK3β 
phosphorylation levels in the cortex of mice infected with T. gondii (Figure 22B, D: relative 
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intensities normalized to GAPDH: pGSK3β (Ser9), control mice 1.187±0.1; infected mice 
1.502±0.04; p=0.03). 
 
 
Figure 22. Effects of T. gondii induced neuroinflammation on GSK3β expression and phosphorylation 
(A) To assess the effect of T. gondii infection on GSK3β protein kinase, mRNA expression for GSK3β was 
assessed by real-time quantitative PCR (corrected for the housekeeping gene HPRT) after extracting total RNA 
from cortex. Data are normalized to control mice. (B) Photomicrographs show western blot samples for total 
GSK3β and Ser9-phosporylated GSK3β in extracts prepared from cortex homogenates of noninfected (control) 
and chronically infected mice. GAPDH is shown as loading control for comparison. Densitometric analysis of 
total GSK3β (C) and pGSK3β (Ser9) (D) protein levels indicates that chronic toxoplasmosis elevates GSK3β 
phosphorylation at Ser 9 site, suggesting an inhibitory activity over GSK3β. Analysis was performed in two 
independent experiments. Data are expressed as mean±SEM, n=4-5 mice per group. *p<0.05, n.s, not significant 
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Discussion 
Behavioral changes triggered by T. gondii in rodents have been extensively discussed in 
recent years (157,159,160,166,171,276,277). Several clinical studies claimed a possible 
association between T. gondii seropositivity and neurological diseases in humans, but no 
sufficient explanation or underlying mechanisms have been described to date (12,13,121,131–
133,137,146,278,279). These specific behavioral and neurological changes occur, not 
exclusively, due to focal brain abnormalities associated with parasite cyst localization, but 
might be a result of pathological interactions between different brain areas. Furthermore, the 
dysregulation of the inflammatory milieu, neurotransmitter imbalance, as well as synaptic 
plasticity could contribute to this effect.  
Converging evidence provided by advances in imaging techniques in recent years confirms a 
close relationship between disturbances in brain networks and debilitating neuropsychiatric 
disorders in humans with cognitive and psychomotor impairments (224,225,228,280–283). 
The core pathology of dysconnectivity syndromes resides mostly in aberrant synaptic 
plasticity due to disturbed interaction between neurotransmitters, neurotransmitter receptors 
and different immunological factors (216,217,223). Therefore, we have explored the impact 
of T. gondii-induced microlesions on the whole mouse brain neuronal circuitry as well as on 
the morphology of individual noninfected neurons, and we correlated the neuroanatomical 
alterations in those areas with changes in the synapse efficacy as possible contributing factors 
for the behavioral and neurological deficits.  
In contrast to other studies, which have investigated the location of T. gondii cysts in specific 
brain areas, we focused our analysis on the position of T. gondii-induced lesions. These 
lesions are detectable in a variety of neuroanatomical areas where complex neuro-
immunological dynamics occur. Initially, we combined the conventional MRI (based on T2- 
and T2*-contrasts) and DT-MRI with a global fiber tracking algorithm in order to identify the 
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brain areas with the highest density of T. gondii-induced lesions and to further assess their 
impact on the neuronal circuitry pattern. The SSC, motor cortices, hippocampus and striatal 
brain structures were depicted as primary sites with altered T2*-MR based contrast, 
suggesting substantial neuroanatomical changes within these brain regions of the infected 
mice. A previous study by Hermes et al. (284) evaluated the chronic T. gondii infection by 
T2-weighted MRI; however, they observed only moderate ventricular dilatation in infected 
mice. The reason for the disparate findings could be that T2-based MR contrast is less 
sensitive compared to T2*-weighted MRI for visualizing the brain microlesions. 
Alternatively, in their study, the authors have used a different mouse strain, thus the genetic 
resistance to infection of Swiss Webster mice could also play an important role.  
Histological examination revealed that T. gondii-induced lesions were constituted by activated 
resident glia cells, as well as recruited mononuclear cells and a few neutrophil granulocytes 
and lymphocytes, similar to the description by Gulinello et al. (104,168).  Cell-mediated 
immunity confers protection against T. gondii through the production of inflammatory 
molecules such as IL-1, IL-4, IL-5, IL-6, IL-8, IL-12, IL-15, IL-18, IL-22, TNF, IFN-γ, NO 
and others which engage distinct pathways and specific effector mechanisms required for the 
appropriate control of the infection (29,74,104,285,286).  
Most of the inflammatory mediators are potentially toxic for neurons (287–289). For example, 
neurons are highly susceptible to NO, and the toxic effects of this molecule have a central role 
in the pathophysiology of several neurodegenerative and demyelinating disorders (290,291). 
Therefore, one would expect a high rate of degenerating neurons associated with the presence 
of T. gondii in the brain. Interestingly, by using specific markers for neuronal death 
(FluoroJadeB), we observed only limited neurodegeneration in the CNS of mice chronically 
infected. Moreover, another study performed in a murine model of Alzheimer’s disease 
suggests that infection with T. gondii inhibits neuronal degeneration (292). A possible 
explanation is provided by a study of Rozenfeld et al. where they demonstrate that IFN-γ 
activated microglia have an active role in neuronal protection by stimulating the production of 
transforming growth factor beta-1 which inhibits iNOS (293). These results suggest that 
neurodegeneration is, at most, a marginal factor in the etiology of behavioral and neurological 
changes associated with chronic toxoplasmosis.  
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We observed random distribution of T. gondii cysts, with no preference to specific brain 
areas, corresponding with the previous results by Gulinello et al. (168) and Berenreiterová et 
al. (170), whereas other groups reported elevated cyst numbers in certain brain regions of 
infected animals (164,166). Furthermore, the location of the cysts was also random in one 
recent study investigating a rat model in which the infection is associated with limited 
inflammation (172). In our experiments, the low number of T. gondii cysts and the 
corresponding moderate number of infected neurons suggest that, in addition to the infected 
cells, other components might alter neuronal morphology and function.  
The inflammatory millieu produced by resident glial cells as well as recruited immune cells, 
can specifically influence neuronal function and communication. It was previously described 
that increases of pro-inflammatory cytokines lead to abnormal synaptic plasticity 
(213,216,217). In the case of chronic T. gondii infection, it is possible that continuous 
production of inflammatory molecules will lead to changes in synaptic plasticity and 
abnormal wiring of brain connections. Further detailed studies should identify the specific 
pathophysiological mechanisms as well as the exact character and source of inflammatory 
mediators.  
Detailed qualitative and quantitative analysis of neuronal fibers using DT-MRI and hrFM 
revealed the impact of T. gondii infection on regional and global mouse brain connectional 
microstructure. This novel approach is currently the only methodology providing a non-
invasive window into the whole brain structural connectivity (201). We took advantage of this 
new technique and demonstrated not only a loss of fiber continuity and density at lesion sites, 
but also substantial alterations in the general wiring scheme. This involved GM cortical and 
subcortical changes as assessed by the reduced FD and FA values, but also significant 
abnormalities along major WM tracts. DT-MRI findings in SSC were paralleled by 
modifications of neuronal cytoskeletal protein levels, verifying the validity of our in vivo 
approach. Notably, infected mice displayed reduced expression of neurofilament (clone 
SMI311) and microtubule (MAP2) in the SSC and hippocampus. Qualitative evaluation of 
immunofluorescence images revealed a clear reduction of SMI311 and MAP2 
immunoreactivity, confirming abnormalities along the cortical and hippocampal dendritic 
trees. Importantly, quantification of MAP2 content in the cortex by western blot confirmed 
the reduced expression levels of this protein. Given the roles of neurofilaments and 
microtubules in the radial growth of axons and dendrites, leading to the stabilization and 
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maturation of neuronal connections (294–296), we suggest that the altered expression of these 
two proteins supports the existence of abnormalities in axonal and dendritic morphology in 
the SSC with possible functional consequences on behavior.  
Moreover, our analysis unveiled a pattern of T. gondii-induced white matter pathology. We 
showed such modifications, first by in vivo DT-MRI and then by electron microscopy. 
Reduced FA values in white matter areas along with significantly increased radial diffusivity 
were associated with myelin abnormalities. The electron micrographs revealed clear 
decompaction as well as degeneration of the myelin lamellae in T. gondii-infected brains. To 
our knowledge, evidence of T. gondii-induced white matter microstructural changes has not 
been shown previously. Interestingly, white matter changes revealed by DT-MRI were located 
along important tracts, such as the corpus callosum, cingulum and internal capsule. Impaired 
inter-hemispherical callosal connectivity would certainly functionally affect the 
somatosensory system, given the direct connections of the left and right SSC through this 
pathway. Cingulum is another fiber pathway known for allowing communication between 
components of the limbic system and projecting in areas such as the entorhinal cortex or 
hippocampus. Such pathological processes characterized by white matter structural alterations 
in the mentioned brain areas are likely to contribute to functional impairments associated with 
behavioral modifications.  
To further explore the structural alterations underlying the changes in the brain connectivity, 
we focused our study to closely investigate the morphological modifications suffered by 
noninfected pyramidal neurons in the somatosensory cortical layers II/III, upon chronic 
infection with T. gondii. Pyramidal cells in layer III are excitatory neurons involved in 
projections between various brain areas contributing to fundamental sensory and cognitive 
processes. Precise morphological analysis of individual pyramidal neurons from the indicated 
areas revealed impaired dendritic branching both for the apical and the basal dendrites in 
infected mice compared with noninfected controls. Extending these findings to the 
hippocampus, we report a reduction of total dendritic complexity of the neurons located in the 
CA1 and DG regions, suggesting that these changes might be intimately related to 
dysfunctions in the memory and learning processes of mice chronically infected with T. 
gondii. Changes in dendritic morphology predict changes in the number of dendritic spines 
that are responsible for information exchange. Dendritic spines are specialized membrane 
protrusions located on neuronal dendrites; they have a very complex structure and 
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fundamental functions in the synaptic physiology and plasticity (197). Spine abnormalities 
have been observed in several neurological and psychiatric disorders (197,297). We found a 
significant reduction in the number of spines within the pyramidal neurons of layers II/III for 
apical, as well as for basal dendrites. Morphological changes such as significant reduction in 
spine length were additionally detected. Because layer II/III pyramidal cells are intercortical 
neurons, the loss of dendritic spine number and morphological abnormalities can be 
associated with disrupted communications between higher cortical areas, thus providing a 
possible explanation for the behavioral alterations. Our results suggest that neuronal changes 
in chronic T. gondii infection is a consequence of the interplay between the host immune 
system and the CNS, rather than a direct effect of the parasites on individual neurons within a 
specific brain region. 
Similar results were reported in other brain structures as well as in the neuronal components 
of the enteric nervous system. In an attempt to identify the possible mechanisms employed by 
T. gondii to reduce fear response as part of the manipulation of the host, Mitra et al. show in a 
rat model of chronic infection that T. gondii causes a retraction of dendritic arborization in 
basolateral amygdala neurons (298). The enteric nervous system is a collection of neurons 
that integrates all aspects of motility, secretion, immune and inflammatory processes of the 
gastrointestinal tract (299–301). Several studies provided experimental evidence that chronic 
infection with T. gondii elicits morphological changes of neuronal subpopulations found in 
the wall of different segments of the gastrointestinal tract (302–306). Nevertheless, all these 
results suggest that morphological alterations of the neurons during latent infection might not 
be an epiphenomenon and may be biologically relevant. Additional methods will need to be 
employed to test the functional implications of these findings and to clarify the precise nature 
of those alterations in T. gondii infected mice.  
Synapses provide the physical basis for communication within the brain, and the ability of 
synapses to maintain their integrity and functionality is critical to maintain proper CNS 
function. Dysfunction in proteins that regulate synaptic plasticity likely contributes to the 
development of neuropsychiatric disorders (307–309). In my project I went beyond previous 
studies by analyzing the long-term effects of cerebral infection with T. gondii in adult cortical 
and hippocampal synapse. The study revealed reduced concentrations of multiple individual 
synaptic proteins, many of which are key to optimal synaptic efficacy. These findings are the 
first to provide molecular and cellular clues regarding the changes at the level of the synapse 
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to elucidate the known behavioral and neurological abnormalities in mice upon chronic 
infection with T. gondii. Importantly, we measured significantly lower synaptophysin and 
PSD95 protein levels in infected mice compared with noninfected mice by western blot, 
indicating clear alteration in integrity and functionality within mature synapses of mice 
infected with T. gondii. Synaptophysin is involved in modulation of the efficiency of the 
synaptic vesicle cycle (266,310), whereas the function of PSD95 is the correct assembly of 
the postsynaptic density complex (311,312). A recent study using synaptophysin-deficient 
mice reported impaired memory and spatial-learning capacities and reduced novelty 
recognition (313), similar to mice infected with T. gondii. Decreased expression of 
synaptophysin associated with cognitive decline has been described in the adult rat brain in a 
model of chronic induced neuroinflammation (314). PSD95 activity is tightly linked to normal 
regulation of synaptic plasticity (259,315). Abnormalities in PSD95 and related postsynaptic-
density-complex molecules can contribute to abnormal synaptic plasticity, which structurally 
correlates to changes in the morphology or distribution of dendrites and dendritic spines 
(316,317).  
Pathway analysis allowed us to uncover previously unknown negative effects of the infection 
on signaling pathways that play critical roles in adult cognitive function. A major finding is 
the lasting negative impact on glutamatergic neurotransmission, specifically on the NMDA 
receptors. Although the synaptoproteome analysis implicated both AMPA and NMDA 
receptors, western blot experiments demonstrate a significant reduced expression of NMDA 
receptor subunits NR1, NR2A and NR2B. The apparently contradictory results might be 
explained by the difference in the sample number. The structure and the role of NMDA 
receptors in a variety of normal and pathological brain processes have been extensively 
reviewed elsewhere (271,272,318). Particularly the roles of NR1, NR2A and NR2B subunits 
of NMDA receptor have been reported, in animal models as well as in humans, to have 
clinical implications.  
NR1 is indispensable for all the constructions of NMDA receptors and distributes 
ubiquitously in the brain (319,320). The deficit with the expression of NR1 in the brain have 
been associated with depression and psychoses in animal models as well as in human patients 
(321–323). The NR2A subunits distributes widely,  but  the  levels  of  its expression are 
higher in the cerebral cortex, the hippocampus and  cerebellar  granule  cells (322). The 
diheteromeric NR1/NR2A subunits have been suggested to be involved in depression and 
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anxiety-like behaviour, and hippocampal-dependent behaviour (324–326). Studies performed 
in mice suggested NR2B to play essential roles in learning, memory and neuronal pattern 
formation, as mice overexpressing the NR2B subunits exhibit superior ability of learning and 
memory while mice lacking the subunit exhibit impaired formation of whisker-related 
neuronal barrelette structure in the somatosensory cortex (327). Recent reports indicate that 
alterations in the NR2B expression are involved in certain aspects of seizure disorder, 
schizophrenia, Alzheimer’s disease and Huntington’s disease (327). Interestingly, several 
studies investigating the neurological basis of anxiety have shown that blockade of NMDA 
receptors, using pharmacological antagonists, causes noninfected rats to approach cat odors 
fearlessly (328,329). Cytokines and inflammatory mediators such as IFN-γ, TNF, NO, IL-1 
and IL-6, commonly present during toxoplasmic encephalitis may affect NMDA receptors via 
activation of indoleamine-2,3-dioxygenase enzyme (IDO). Increased expression of IDO elicits 
the degradation of tryptophan, the essential amino-acid, which is the precursor of serotonin 
(330,331). Tryptophan degradation by IDO leads to increased concentrations of two 
neuroactive metabolites, quinolinic acid (QA) and kynurenic acid (KA) (332). A recent study 
confirmed that one month after infection with a type II T. gondii strain, there was a 
dramatically increased concentration of both KA and QA in the brains of infected mice (333). 
In human patients, excessive QA and KA levels have been correlated with a number of 
neurodegenerative disorders, depression and schizophrenia (332,334–336). Produced 
primarily by microglia, QA binds to NMDARs inducing excitotoxicity and oxidative stress in 
the brain (332,337). Kynurenic acid, which is produced primarily in astrocytes, is a potent 
antagonist of NMDARs, leading thus to disturbances in glutamatergic and dopaminergic 
neurotransmission (332,337).  
Another interesting finding resulted from pathway analysis is the involvement of 
phosphatidylinositol 3-OH kinase (PI3K) enzymes family via serine-threonine kinase Akt 
complex. PI3K signaling is involved in cellular functions such as cell growth, proliferation, 
differentiation, motility, survival and intracellular trafficking (338,339). Activation of PI3K 
occurs through binding to cellular receptors located on plasma membrane, including toll like 
receptors (TLRs) (339), and mediates the recruitment of Akt. After recruitment, Akt, which is 
a key regulator of PI3K pathway, is activated by phosphorylation at Thr308 and Ser473 
(273,275). Activated Akt phosphorylates the constitutively active serine-threonine kinase 
GSK3β (Ser9). Phosphorylation of GSK3β (Ser9) results in its inhibition (275,340). 
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Akt/GSK3β signaling pathway plays pivotal roles in the brain by regulating several 
metabolic, signaling, and structural proteins and transcription factors, and thus influences 
neuronal plasticity and neurodegeneration (275). Additionally, dysregulation of Akt/GSK3β 
activity contribute to the pathogenesis of neuropsychiatric disorders, such as mood disorders 
and schizophrenia (341,342). In our study, following chronic infection with T. gondii, we 
could detect a vigorous expression of pAkt (Thr308) and pAkt (Ser473) protein levels in the 
cortex, indicating an increased activation of Akt. In line with this result we could show 
inhibition of GSK3β activity, as reflected by increased pGSK3β (Ser9) protein levels. We 
speculate that the increased activation of Akt might be, at least partially, due to presence of 
parasites which are recognized and activate TLRs (236). Moreover, the inhibition of GSK3β 
could represent a protective mechanisms meant to reduce the impact of proinflammatory 
molecules on brain parenchyma. GSK3β has been recognized as the control switch for the 
regulation of pro- and anti-inflammatory response (343). Several lines of evidence from 
studies with other pathogens, like Burkholderia pseudomallei and Francisella tularensis, 
indicated that pharmacological inhibition of GSK3β is beneficial as indicated by the improved 
survivability of acutely infected mice and reduction of pro-inflammatory cytokine levels 
(344,345). Akt/GSK3β pathway is also a therapeutic target for neurological disorders (346). 
For example, drugs like lithium chloride (LiCl), valproic acid, haloperidol, clozapine and 
olanzapine are known to inhibit GSK3, directly, or indirectly by activating Akt, and are now 
widely used in the treatment of several mental disorders (346).  Interestingly, Webster et al. 
have demonstrated that T. gondii-infected rats treated with anti-psychotic (haloperidol) and 
mood stabilizing (valproic acid) medications did not developed altered behavioral profiles 
displayed by their untreated but infected littermates (347). Although the authors conclude that 
the effect on behavior is due to inhibited replication of T. gondii (138,347), thus reducing the 
parasite burden in the brain, no evidence to support this hypothesis is provided. Instead we 
suggest that the effect of the antipsychotic drugs could be due to modulation of Akt/GSK3β 
pathway. Further experiments should address this hypothesis and clarify the involvement of 
Akt/GSK3β upstream and downstream signaling molecules in the T. gondii-induced 
neuropathology. 
In conclusion, the results presented herein indicate that upon latent infection with T. gondii, 
marked neuroanatomical and synaptic functional changes occur in CNS regions that are 
relevant to normal biological functions of the brain. We suggest that the described alterations 
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might contribute to the reported behavior and neuropsychiatric changes observed in chronic T. 
gondii infection, and establish a murine model for translational studies of chronic 
toxoplasmosis. Identification of the synaptic signaling pathways may allow more specific 
manipulations to alter their activity in order to demonstrate the causal effects of chronic 
infection with T. gondii as well as to establish targets for therapeutic development.  
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Annex 
Differentially expressed synaptosomal proteins identified by iTRAQ. 
No. Symbol Entrez Gene Name Accession Location Fold change 
1 ABCA13 ATP-binding cassette, sub-family A 
(ABC1), member 13 
Q5SSE9 Extracellular -1.460 
2 ACADVL acyl-CoA dehydrogenase, very long 
chain 
P50544 Cytoplasm 1.723 
3 ACLY ATP citrate lyase Q91V92 Cytoplasm -1.513 
4 ALB albumin P07724 Extracellular 5.839 
5 ANKS1B ankyrin repeat and sterile alpha motif 
domain containing 1B 
Q8BIZ1 Nucleus -1.792 
6 APOD apolipoprotein D P51910 Extracellular 3.948 
7 APOE apolipoprotein E P08226 Extracellular 2.287 
8 ARHGDIB Rho GDP dissociation inhibitor 
(GDI) beta 
Q61599 Cytoplasm 1.799 
9 ATCAY ataxia, cerebellar, Cayman type Q8BHE3 Plasma Membrane -2.012 
10 B2M beta-2-microglobulin P01887 Plasma Membrane 7.610 
11 BCAS1 breast carcinoma amplified sequence 
1 
Q80YN3 Plasma Membrane 1.852 
12 C19orf10 chromosome 19 open reading frame 
10 
Q9CPT4 Extracellular 1.720 
13 C4A/C4B complement component 4B (Chido 
blood group) 
P01029 Extracellular 1.991 
14 CALU calumenin O35887 Cytoplasm 2.099 
15 CHGA chromogranin A (parathyroid 
secretory protein 1) 
P26339 Cytoplasm 1.843 
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No. Symbol Entrez Gene Name Accession Location Fold change 
16 CHGB chromogranin B (secretogranin 1) P16014 Extracellular 2.304 
17 CLU clusterin Q06890 Cytoplasm 1.939 
18 CST3 cystatin C P21460 Extracellular 2.070 
19 CTSD cathepsin D P18242 Cytoplasm 1.827 
20 CTSZ cathepsin Z Q9WUU7 Cytoplasm 3.062 
21 DLG2 discs, large homolog 2 (Drosophila) Q91XM9 Plasma Membrane -1.488 
22 DLG4 discs, large homolog 4 (Drosophila) Q62108 Plasma Membrane -1.942 
23 DNAJC5 DnaJ (Hsp40) homolog, subfamily C, 
member 5 
P60904 Plasma Membrane -1.626 
24 DSP desmoplakin E9Q557 Plasma Membrane 1.736 
25 ESYT2 extended synaptotagmin-like protein 
2 
Q3TZZ7 Plasma Membrane -1.517 
26 GABBR2 gamma-aminobutyric acid (GABA) 
B receptor, 2 
Q80T41 Plasma Membrane -1.645 
27 GABRA1 gamma-aminobutyric acid (GABA) 
A receptor, alpha 1 
P62812 Plasma Membrane -1.473 
28 GBP2 guanylate binding protein 2, 
interferon-inducible 
Q9Z0E6 Cytoplasm 3.800 
29 GFAP glial fibrillary acidic protein P03995 Cytoplasm 2.302 
30 GIMAP4 GTPase, IMAP family member 4 Q99JY3 Nucleus -1.471 
31 GLS glutaminase D3Z7P3 Cytoplasm -1.558 
32 GLUL glutamate-ammonia ligase P15105 Cytoplasm -2.519 
33 GRIA2 glutamate receptor, ionotropic, 
AMPA 2 
P23819 Plasma Membrane -1.582 
34 GRIA3 glutamate receptor, ionotropic, 
AMPA 3 
Q9Z2W9 Plasma Membrane -2.004 
35 GRIN1 glutamate receptor, ionotropic, N-
methyl D-aspartate 1 
P35438 Plasma Membrane -1.490 
36 GSTM5 glutathione S-transferase mu 5 P10649 Cytoplasm -1.495 
37 H2AFZ H2A histone family, member Z P0C0S6 Nucleus 4.505 
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No. Symbol Entrez Gene Name Accession Location Fold change 
38 HCLS1 hematopoietic cell-specific Lyn 
substrate 1 
P49710 Nucleus 1.867 
39 HIST1H1C histone cluster 1, H1c P15864 Nucleus 2.254 
40 HLA-A major histocompatibility complex, 
class I, A 
P01899 Plasma Membrane 3.919 
41 HOMER1 homer homolog 1 (Drosophila) Q9Z2Y3 Plasma Membrane -1.718 
42 HSP90B1 heat shock protein 90kDa beta 
(Grp94), member 1 
P08113 Cytoplasm 1.810 
43 IFIT3 interferon-induced protein with 
tetratricopeptide repeats 3 
Q64345 Cytoplasm 5.093 
44 Ighg2a immunoglob heavy constant γ-2A P01864 Extracellular 3.606 
45 Iigp1 interferon inducible GTPase 1 Q9QZ85 Other 3.248 
46 Irgm1 immunity-related GTPase family M 
member 1 
Q60766 Cytoplasm 4.670 
47 JUP junction plakoglobin Q02257 Plasma Membrane 1.781 
48 KCTD16 potassium channel tetramerization 
domain containing 16 
Q5DTY9 Plasma Membrane -1.433 
49 KIAA0513 KIAA0513 Q8R0A7 Other -1.642 
50 KRT16 keratin 16 Q9Z2K1 Cytoplasm 2.513 
51 KRT17 keratin 17 Q9QWL7 Cytoplasm 2.030 
52 Krt2 keratin 2 Q3TTY5 Cytoplasm 1.959 
53 KRT35 keratin 35 Q497I4 Cytoplasm -2.309 
54 Krt42 keratin 42 Q6IFX2 Other 2.700 
55 KRT5 keratin 5 Q922U2 Cytoplasm 2.031 
56 KRT6B keratin 6B P50446 Cytoplasm 1.773 
57 KRT75 keratin 75 Q8BGZ7 Cytoplasm 1.813 
58 KRT76 keratin 76 Q3UV17 Cytoplasm 2.275 
59 LAMP2 lysosomal-associated membrane 
protein 2 
P17047 Plasma Membrane 4.186 
60 LAP3 leucine aminopeptidase 3 Q9CPY7 Cytoplasm 1.825 
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No. Symbol Entrez Gene Name Accession Location Fold change 
61 LCP1 lymphocyte cytosolic protein 1 (L-
plastin) 
Q61233 Cytoplasm 2.524 
62 LGALS1 lectin, galactoside-binding, soluble, 1 P16045 Extracellular 1.816 
63 LGI1 leucine-rich, glioma inactivated 1 Q9JIA1 Plasma Membrane -1.471 
64 LRRC7 leucine rich repeat containing 7 Q80TE7 Plasma Membrane -1.701 
65 MAL2 mal, T-cell differentiation protein 2 
(gene/pseudogene) 
Q8BI08 Plasma Membrane -1.473 
66 NAMPT nicotinamide 
phosphoribosyltransferase 
Q99KQ4 Extracellular 2.606 
67 NDUFA4 NDUFA4, mitochondrial complex 
associated 
Q62425 Cytoplasm -1.527 
68 NDUFB5 NADH dehydrogenase (ubiquinone) 
1 beta subcomplex, 5 
Q9CQH3 Cytoplasm -1.715 
69 Nptn neuroplastin P97300 Plasma Membrane -1.443 
70 OGT O-linked N-acetylglucosamine 
(GlcNAc) transferase 
Q8CGY8 Cytoplasm -1.587 
71 PCSK1N proprotein convertase subtilisin/kexin 
type 1 inhibitor 
Q9QXV0 Extracellular 1.872 
72 PDIA3 protein disulfide isomerase family A, 
member 3 
P27773 Cytoplasm 1.723 
73 PFN1 profilin 1 P62962 Cytoplasm 1.995 
74 PLBD2 phospholipase B domain containing 2 Q3TCN2 Extracellular 1.708 
75 PLCB1 phospholipase C, beta 1 
(phosphoinositide-specific) 
Q9Z1B3 Cytoplasm -1.626 
76 PPIB peptidylprolyl isomerase B 
(cyclophilin B) 
P24369 Cytoplasm 2.290 
77 PPP1R1B protein phosphatase 1, regulatory 
(inhibitor) subunit 1B 
Q60829 Cytoplasm 2.094 
78 PPT1 palmitoyl-protein thioesterase 1 O88531 Cytoplasm 1.728 
79 PRDX1 peroxiredoxin 1 P35700 Cytoplasm 1.772 
80 PRDX3 peroxiredoxin 3 P20108 Cytoplasm 1.767 
81 PRDX6 peroxiredoxin 6 O08709 Cytoplasm 2.318 
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82 PRKACA protein kinase, cAMP-dependent, 
catalytic, alpha 
P05132 Cytoplasm -1.821 
83 Ptma prothymosin alpha P26350 Nucleus 1.759 
84 Ptprd protein tyrosine phosphatase, 
receptor type, D 
Q64487 Plasma Membrane -1.431 
85 PURB purine-rich element binding protein B O35295 Nucleus -2.336 
86 PVALB parvalbumin P32848 Cytoplasm 1.835 
87 RAB3A RAB3A, member RAS oncogene 
family 
P63011 Cytoplasm -1.499 
88 RAB3B RAB3B, member RAS oncogene Q9CZT8 Cytoplasm -1.938 
89 RHOG ras homolog family member G P84096 Cytoplasm 2.142 
90 RIMS1 regulating synaptic membrane 
exocytosis 1 
Q99NE5 Plasma Membrane -1.522 
91 RPL18 ribosomal protein L18 P35980 Cytoplasm 2.064 
92 Rpl23a ribosomal protein L23A P62751 Nucleus 1.746 
93 RPL30 ribosomal protein L30 P62889 Cytoplasm 1.914 
94 RPL5 ribosomal protein L5 P47962 Cytoplasm 2.301 
95 RPL7 ribosomal protein L7 P14148 Nucleus 1.891 
96 RPLP2 ribosomal protein, large, P2 P99027 Cytoplasm 2.067 
97 RTN4 reticulon 4 Q99P72 Cytoplasm 1.714 
98 S100A4 S100 calcium binding protein A4 P07091 Cytoplasm 4.802 
99 S100A6 S100 calcium binding protein A6 P14069 Cytoplasm 2.612 
100 SCAI suppressor of cancer cell invasion Q8C8N2 Other -1.451 
101 SCG2 secretogranin II Q03517 Extracellular 2.068 
102 SFXN1 sideroflexin 1 Q99JR1 Cytoplasm -1.531 
103 SH3BGRL3 SH3 domain binding glutamate-rich 
protein like 3 
Q91VW3 Nucleus 1.797 
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104 SLC12A5 solute carrier family 12 
(potassium/chloride transporter), 
member 5 
Q91V14 Plasma Membrane -1.529 
105 SLC17A6 solute carrier family 17 (vesicular 
glutamate transporter), member 6 
Q8BLE7 Plasma Membrane -1.572 
106 SLC1A2 solute carrier family 1 (glial high 
affinity glutamate transporter), 
member 2 
P43006 Plasma Membrane -2.347 
107 SLC4A4 solute carrier family 4 (sodium 
bicarbonate cotransporter), member 4 
O88343 Plasma Membrane -1.490 
108 SLC4A8 solute carrier family 4, sodium 
bicarbonate cotransporter, member 8 
Q8JZR6 Plasma Membrane -1.546 
109 SLC6A11 solute carrier family 6 
(neurotransmitter transporter), 
member 11 
P31650 Plasma Membrane -1.681 
110 STAT1 signal transducer and activator of 
transcription 1, 91kDa 
P42225 Nucleus 2.205 
111 SV2A synaptic vesicle glycoprotein 2A Q9JIS5 Cytoplasm -1.462 
112 SV2B synaptic vesicle glycoprotein 2B Q8BG39 Plasma Membrane -1.460 
113 SYNGAP1 synaptic Ras GTPase activating 
protein 1 
F6SEU4 Plasma Membrane -1.439 
114 SYNGR3 synaptogyrin 3 Q8R191 Plasma Membrane -1.587 
115 SYP synaptophysin Q62277 Cytoplasm -1.695 
116 TAPBP TAP binding protein (tapasin) Q9R233 Cytoplasm 3.530 
117 TF transferrin Q921I1 Extracellular 1.702 
118 TPM3 tropomyosin 3 P21107 Cytoplasm 1.704 
119 WDR7 WD repeat domain 7 Q920I9 Other -1.460 
120 WFS1 Wolfram syndrome 1 (wolframin) P56695 Cytoplasm 1.924 
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